<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2311200286
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Beovu
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        Brolucizumab
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        120
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravitreal use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        0
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store in a refrigerator (2°C – 8°C), do not freeze
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        2754.151
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="NOVARTIS Pharma Stein AG" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            NOVARTIS Pharma Stein AG
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 439]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Novartis Saudi Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Novartis Europharm Limited
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        S01LA
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Beovu contains the active substance brolucizumab, which belongs to a group of medicines called antineovascularisation agents. Beovu is injected into the eye by your doctor to treat an eye disorder called neovascular (wet) age-related macular degeneration (AMD).</p><p><!--[if gte vml 1]><o:wrapblock><v:group
  id="Group_x0020_46" o:spid="_x0000_s1026" style='position:absolute;
  margin-left:70.9pt;margin-top:13.2pt;width:243pt;height:122.25pt;z-index:251659264;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' coordorigin="1418,264" coordsize="4860,2445"
  o:gfxdata="UEsDBBQABgAIAAAAIQDI4TOSFQEAAFICAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSSTW7DIBCF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">
  <v:shapetype id="_x0000_t75" coordsize="21600,21600" o:spt="75"
   o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
   <v:stroke joinstyle="miter"/>
   <v:formulas>
    <v:f eqn="if lineDrawn pixelLineWidth 0"/>
    <v:f eqn="sum @0 1 0"/>
    <v:f eqn="sum 0 0 @1"/>
    <v:f eqn="prod @2 1 2"/>
    <v:f eqn="prod @3 21600 pixelWidth"/>
    <v:f eqn="prod @3 21600 pixelHeight"/>
    <v:f eqn="sum @0 0 1"/>
    <v:f eqn="prod @6 1 2"/>
    <v:f eqn="prod @7 21600 pixelWidth"/>
    <v:f eqn="sum @8 21600 0"/>
    <v:f eqn="prod @7 21600 pixelHeight"/>
    <v:f eqn="sum @10 21600 0"/>
   </v:formulas>
   <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
   <o:lock v:ext="edit" aspectratio="t"/>
  </v:shapetype><v:shape id="Picture_x0020_10" o:spid="_x0000_s1027" type="#_x0000_t75"
   style='position:absolute;left:1418;top:264;width:4860;height:2445;
   visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
   <v:imagedata src="file:///C:/Users/alrasha1/AppData/Local/Temp/9/msohtmlclip1/01/clip_image001.jpg"
    o:title=""/>
  </v:shape><v:shapetype id="_x0000_t202" coordsize="21600,21600" o:spt="202"
   path="m,l,21600r21600,l21600,xe">
   <v:stroke joinstyle="miter"/>
   <v:path gradientshapeok="t" o:connecttype="rect"/>
  </v:shapetype><v:shape id="Text_x0020_Box_x0020_11" o:spid="_x0000_s1028"
   type="#_x0000_t202" style='position:absolute;left:4108;top:1116;width:2163;
   height:1338;visibility:visible;mso-wrap-style:square;v-text-anchor:top'
   o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" stroked="f">
   <v:textbox inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span style='font-size:11.5pt;mso-bidi-font-size:11.0pt'><o:p>&nbsp;</o:p></span></p>
      <p class=MsoNormal style='margin-top:0in;margin-right:.75pt;margin-bottom:
      0in;margin-left:.05pt;margin-bottom:.0001pt;line-height:102%'>Abnormal
      blood vessels that leak fluid or blood into the macula<o:p></o:p></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><w:wrap type="topAndBottom" anchorx="page"/>
 </v:group><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="325" height="163" src="file:///C:/Users/alrasha1/AppData/Local/Temp/9/msohtmlclip1/01/clip_image002.png" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>What Beovu is used for</p><p>Beovu is used to treat neovascular wet AMD in adults, which occurs when abnormal blood vessels form and grow underneath the macula. The macula, which is at the back of the eye, is responsible for clear vision. The abnormal blood vessels may leak fluid or blood into the eye and interfere with the macula&rsquo;s function, resulting in decreased vision.</p><p>&nbsp;</p><p>How Beovu works</p><p>A substance called vascular endothelial growth factor A (VEGF-A) causes the growth of blood vessels in the eye. By attaching to VEGF-A, Beovu blocks its effect and so reduces the growth of abnormal blood vessels in AMD, which in turn reduces the leakage of fluid or blood in the eye.</p><p>&nbsp;</p><p>Beovu may slow down disease progression and thereby maintain, or even improve, your vision.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Do not use Beovu:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to brolucizumab or any of the other ingredients of this medicine (listed in section 6).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have an active or suspected infection in or around the eye.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have pain or redness in your eye (eye inflammation).</p><p>If any of these applies to you, tell your doctor. You should not be given Beovu.</p><p>&nbsp;</p><p>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take special care with Beovu</p><p>Talk to your doctor before you are given Beovu if any of the following applies to you:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have glaucoma (an eye condition usually caused by high pressure in the eye).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a history of seeing flashes of light or floaters (dark floating spots) and if you have a sudden increase in the size and number of floaters.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have had eye surgery in the last 4 weeks or if eye surgery is planned in the next four weeks.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have ever had any eye diseases or eye treatments.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a history of sudden vision loss due to blockage of blood vessels in the back of the eye (retinal vascular occlusion) or inflammation of blood vessels in the back of the eye (retinal vasculitis) in the last year.</p><p>&nbsp;</p><p>&nbsp;</p><p>Tell your doctor immediately if you:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; develop redness of the eye, eye pain, increased discomfort, worsening eye redness, blurred or decreased vision, an increased number of small particles in your vision, increased sensitivity to light.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; develop sudden vision loss, which could be a sign of retinal vascular occlusion.</p><p>Any of the above symptoms may result in your doctor discontinuing your treatment with Beovu.</p><p>&nbsp;</p><p>&nbsp;</p><p>Furthermore it is important for you to know that:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The safety and efficacy of Beovu when administered to both eyes at the same time has not been studied and use in this way may lead to an increased risk of experiencing side effects.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Injections with Beovu may cause an increase in eye pressure (intraocular pressure) in some patients within 30 minutes of the injection. Your doctor will monitor this after each injection.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will check whether you have other risk factors that may increase the chance of a tear or detachment of one of the layers at the back of the eye (retinal detachment or tear, and retinal pigment epithelial detachment or tear), in which case Beovu must be given with caution.</p><p>&nbsp;</p><p>The systemic use of VEGF inhibitors, substances similar to those contained in Beovu, is potentially related to the risk of blood clots blocking blood vessels (arterial thromboembolic events), which may lead to heart attack or stroke. There is a theoretical risk of such events following injection of Beovu into the eye.</p><p>&nbsp;</p><p>Children and adolescents</p><p>Beovu is not used in children and adolescents, because wet AMD occurs only in adults.</p><p>&nbsp;</p><p>c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Taking other medicines, herbal or dietary supplements</p><p>Tell your doctor if you are using, have recently used or might use any other medicines.</p><p>&nbsp;</p><p>d.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pregnancy and breast-feeding</p><p>If you are pregnant or breast-feeding, think that you may be pregnant or are planning to have a baby, ask your doctor for advice before this medicine is given to you.</p><p>&nbsp;</p><p>Breast-feeding is not recommended during treatment with Beovu and for at least one month after stopping treatment with Beovu because it is not known whether Beovu passes into human milk.</p><p>&nbsp;</p><p>Women who could become pregnant must use an effective method of birth control during treatment and for at least one month after stopping treatment with Beovu. If you become pregnant or think you are pregnant during treatment, tell your doctor right away.</p><p>&nbsp;</p><p>e.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Driving and using machines</p><p>After your injection with Beovu, you may have temporary vision problems (for example blurred vision). Do not drive or use machines as long as these last.</p><p>&nbsp;</p><p><strong>f.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Important information about some of the ingredients of Beovu</strong></p><p><strong>&nbsp;</strong></p><p>Beovu contains sodium</p><p>The medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially &ldquo;sodium-free&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>How much and how often Beovu is given</strong></p><p>The recommended dose is 6 mg brolucizumab.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You will be treated with one injection every month for the first 3 months.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After that, you may get one injection every 3 months. Your doctor will determine your treatment interval based on the condition of your eye; some patients may need treatment every 2 months.&nbsp; The treatment interval between two doses of Beovu should not be less than every 2&nbsp;months.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>For the first&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Then,</strong></p><p><!--[if gte vml 1]><o:wrapblock><v:group
  id="Group_x0020_40" o:spid="_x0000_s1026" style='position:absolute;left:0;
  text-align:left;margin-left:125.45pt;margin-top:19.05pt;width:284pt;height:78.45pt;
  z-index:251660288;mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' coordorigin="2509,381" coordsize="5680,1569"
  o:gfxdata="UEsDBBQABgAIAAAAIQDI4TOSFQEAAFICAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSSTW7DIBCF
95V6B8S2snG6qKrKdhb9WbZdpAeYwtimxYCApMntO3ZsqY2sbLJBwPDe+xgo1/vesB2GqJ2t+Cov
OEMrndK2rfjH5iW75ywmsAqMs1jxA0a+rq+vys3BY2SktrHiXUr+QYgoO+wh5s6jpUrjQg+JlqEV
HuQ3tChui+JOSGcT2pSlwYPX5RM2sDWJPe9p+0jy5bHl7PF4cMiquO4Hg7EgFjUBTTzRgPdGS0h0
O7Gz6oQsm6hyUo5nYqd9vCF0vpwwVP5D/Q2YdG/UzqAVsncI6RV6QhfSaP/pICihAvxQc+M8WeXn
TReoXdNoicrJbU9dzCfHGft8fKIXQjGOlyePNnOuGH9E/QsAAP//AwBQSwMEFAAGAAgAAAAhAK0w
P/HBAAAAMgEAAAsAAABfcmVscy8ucmVsc4SPzQrCMBCE74LvEPZu03oQkaa9iOBV9AHWZNsG2yRk
49/bm4ugIHibZdhvZur2MY3iRpGtdwqqogRBTntjXa/gdNwt1iA4oTM4ekcKnsTQNvNZfaARU37i
wQYWmeJYwZBS2EjJeqAJufCBXHY6HydM+Yy9DKgv2JNcluVKxk8GNF9MsTcK4t5UII7PkJP/s33X
WU1br68TufQjQpqI97wsIzH2lBTo0Yazx2jeFr9FVeTmIJtafi1tXgAAAP//AwBQSwMEFAAGAAgA
AAAhADLup0Y9BgAAxR8AAB8AAABjbGlwYm9hcmQvZHJhd2luZ3MvZHJhd2luZzEueG1s7Fntbts2
FP0/YO9A6L9rSdaHZdQpEjsOCmRdkLQPwEh0rE0iNZJO4g579x2Skq04Tds1bYcWTtGEEqmry8N7
7zmkXr66rytyy6QqBZ96wQvfI4znoij5zdR793YxGHtEacoLWgnOpt6GKe/V0a+/vKSTG0mbVZkT
WOBqQqfeSutmMhyqfMVqql6IhnH0LYWsqcalvBkWkt7Bcl0NQ99PhjUtuXe0MzWnmpK1LL/AVCXy
P1kxo/yWKpis8kn/TutjlT/fMp3w2zPZXDUX0niev7m9kKQsph6Q47QGRN6w7WiH4XK499TNzsD9
UtZmvFguyT1WIM5GYRB7ZDP1ojSLxuPY2WP3muQYMEr8ZOzjZTlGZFkywmD3wtXvnzCRr04/bgRu
OnfQ6Llom8bHJ2Yebad+JsW6Ibjeg8A8bK2cY5mUAwTInXUwPIEPub77TRSAlK61sIHy9dEKYz+z
aI/GQQdkB1MMpB3QQZxkpvcJhJoyd/hclPl+XERBFxjo1GvJSDDa4rMdDwsWG8LFbEX5DTtWDcs1
AgJPd7ekFHcrRgtlbm9RbG1YDLf2rquyWZRVZdwy7TYD5OckAEKxzNlc5Ouace1SVbKKatQItSob
5RE5YfU1Q9TL10VgVwbxea60eZ2JVJvEf4fjY9/PwpPBLPZng8hPTwfHWZQOUv80jfxoHMyC2T/m
6SCarBUDALSaN2VXUYLokbd1mUuhxFK/yEU9dI52VQWOBr6rKeSWViYjHUZwyK5c5yKQMpAYX5XM
LwEzxqGtJdP5yjSXQK69j8HbjvbBDleFGvDJEH0cXwYfk8nROEtcdCWjztUuvhup9BkTNTENoAwf
Lcr0FiC7WXVDjL9cGJ/sLCr+4AZcdne6yffXJ/Oz0/HpOBpEYXKK9ZnPB8eLWTRIFkEaz0fz2Wwe
dOuzKouCcfOa5y+PRVtUZbFFUt5czyrplm1hf9q1U7thQxMmOze6JTXGDKQu5LIgjPyTMBssknE6
iBZRPMhSfzzwg+wkS/woi+aLh1M6Lzl7/pTIHapxHMZ2lXpOmxDrzc23P4/nRid1qZkkVVlPPZR3
/JhBdGLS/ZQXtq1pWbl2Dwrj/g4KLHe30CZwLUmhgepiMbcxz28fk1cUdkXKhD3qT4UyFTkXUKi7
B1SzV6Q+XJHccLx39yrjyqdzJQ2QEYbXkvbdXa4E49HI5co4fFiIMbln5MpnLttTIelePqdq5ULX
LrxD7T+u58+fpR8KTTrR91c2KPX9iSg2Jkiv8RexIgXqHtgX2hSNlZDvPXIHxTn11F9rKplHqtcc
RJgFkdEf2l5EcRriQvZ7rvs9lOcwNfW0R1xzpnGFR9aNLG9WeJNjMy6OITmWZVtrnU/Gu0rpK72p
mE1I6znjxQWV9BI+V0icqcf44N1Vm+IYgXnvJgeWu2p2zOJmjxHKmnK/d0mzE5cRot+py15+dsLv
u+Vn7Kfww+Qn/loEuvwcBT42ClaS7gmlQ37+ICx6yE+k9xfnZ9Tl51uTEifinoDKbIq09ElMETAb
PKcQvi2RjgIQqEnUwN9n0iwB1ZtEjbKwLVIH0Tn1nmL4ntJyYtWliaECs9AH0floa2WUnoHn2cy+
ZfUto6Ph2ByNb8DkRqLWVJ5bQYDGJfInTH2bsBW/aloNnV/k2sk9ZFcr1BEV/REnbGkgUE1+odXD
zSju7XqPl3bH/MQ42wvLLaAWVbknM4h6b7I8NtB0xYUtlxDxbqMIv7Bv50RvGrakOc5S3pY1U+QN
uyOXoqbcIw3lQqHDD/Ev8UcwFuF/iBaKSFNiT7ygdVmZcmJIfkWlYlacOQlAv5lxzB3ztcF0FJCS
/4Fp4QyCNNgp1YLrlRVXVmLZUU9IMYdRgC2VTdufCJ3dhC0IX01t4vzRqc0dm6X/H5vFI3Peadls
X3eGSQpfDZ2lseVbhMyBzg509rXPUH5sOgvjMMURoyE3cFoY4xJXJceBHup4mIVdbexzWI/l0gPL
se/PcgxHHxsyckyniJCEqgPhdYctHeFBHhlW/4B2c3T/QG9t1Vhkz05AFg+6D3Lso1qvL8ckwwcY
fB4qWEGuN2Qj1pIUItdCHkJ0P0SB2+edAGJg+611uPcB20Z7+8HdfCXvXx/9CwAA//8DAFBLAwQK
AAAAAAAAACEAmVsoI3kYAAB5GAAAGwAAAGNsaXBib2FyZC9tZWRpYS9pbWFnZTEuanBlZ//Y/+AA
EEpGSUYAAQEBAGAAYAAA/9sAQwADAgIDAgIDAwMDBAMDBAUIBQUEBAUKBwcGCAwKDAwLCgsLDQ4S
EA0OEQ4LCxAWEBETFBUVFQwPFxgWFBgSFBUU/9sAQwEDBAQFBAUJBQUJFA0LDRQUFBQUFBQUFBQU
FBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQU/8AAEQgANAGUAwEiAAIRAQMR
Af/EAB8AAAEFAQEBAQEBAAAAAAAAAAABAgMEBQYHCAkKC//EALUQAAIBAwMCBAMFBQQEAAABfQEC
AwAEEQUSITFBBhNRYQcicRQygZGhCCNCscEVUtHwJDNicoIJChYXGBkaJSYnKCkqNDU2Nzg5OkNE
RUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6g4SFhoeIiYqSk5SVlpeYmZqio6Slpqeoqaqy
s7S1tre4ubrCw8TFxsfIycrS09TV1tfY2drh4uPk5ebn6Onq8fLz9PX29/j5+v/EAB8BAAMBAQEB
AQEBAQEAAAAAAAABAgMEBQYHCAkKC//EALURAAIBAgQEAwQHBQQEAAECdwABAgMRBAUhMQYSQVEH
YXETIjKBCBRCkaGxwQkjM1LwFWJy0QoWJDThJfEXGBkaJicoKSo1Njc4OTpDREVGR0hJSlNUVVZX
WFlaY2RlZmdoaWpzdHV2d3h5eoKDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLD
xMXGx8jJytLT1NXW19jZ2uLj5OXm5+jp6vLz9PX29/j5+v/aAAwDAQACEQMRAD8A/VOiivn/APbR
/aRP7LvwSv8AxVb20d7rlxMlhpkEx/d+e+f3j/7CdfyHegDvvi78bPBXwK8P2+t+ONYOh6VPcJaR
3JtZ7nfI/RMRxuecfpXc213He28c8DiSORN6H1r8R/Cvxsu/2s/hT4n8LfE74s6foXipPEdprun3
HiiR47L7OkZjkjj8sfJ1z5dcP+03+1x4r8QfHLxNd+AfiH4gt/B6Sxwaf9ivZLeOSOOOOPzI48/9
M6AP35rzf4e/HXwP8VfEXifRvCuuHVtU8MXH2XV7b7JPEbeTnjMkYEnKH7hIr8H/AIb/ALWXxI8O
/EHw1qut+P8AxTfaLaanb3F5bnVJJPMt0k/efpmvpD4hfGPRvgJ4Y+L/AIk+Hvxb03U/E/xE8QW+
o6H/AMI1JJ9ps7bzJJJftHmR/u/9Z5fl0AfsxRXx5/wTl/a+1L9qDwBq9n4lVD4x8OyRR3k8SbI7
qKQHy5R7/u3/ACrzb/gpp+3B4i+BU+m/DzwBdf2Z4kv7Q3d/qwAaS0gz8iR56SHBOf8AGgD7F1b4
7+BtD+LOmfDW/wBb+y+N9Tt/tdnpjWc582PnkSCPy/4D/HnivR6/H/QvjP4P8W6j8P8A43658UrG
PXPC/gu40fU9JvJJP7Zn1MRSxxyRj/lp5nmf6z2r4y/4ac+Lf/RSPFP/AINJKAP6KfG3jLSPh74T
1TxLrt0dP0bS7d7u7uNjyCKNOp2Jkn8Kr/Dv4haD8UPBWleKvDN//amialD5tpefZ5I/MT/ckAf9
K/EL9mv9oXVfFer+OPCPxJ+JepW2k+KvDF7o9nfa/eSXNnbXknl+XJJ/37rtPHn7YHiH9m63+Efh
H4W/EC08QQeEdINvrh0s79Jv7iS4kk8v5x8/7s/6wUAftrRXmvwA+MFh8efg74X8c2MQtotZtfMk
tjz5EoOySPPs4Nfmf+0P/wAFKvE0/wC1DY6ToOrz6H8NfDPiCOC9/s3Jl1OOOTFw8nHMfD/u/pQB
+mfwz+Ofgf4wXniSy8I64dVuvDl3/Z+qJ9juIPs1xz8n7yNN/wBw/cyOK9Hr8VPip8S9E+CPww+K
B8C/Few1jxF4/wDFketaYPCdzJHcWln+8k/0j/nn/rP9XXy9/wANO/Fv/opXij/waS0Af0DfFn48
+BvgdZ6RP42106JBq12LCyk+yT3HnXB/5Z/u43wfrXo1fiH8MviDpvx/+B2heHPHfxXtdE8T+GPG
UfiGS58YXDv9o0/yo/8Aj3k5+fP/ACzrt/hp/wAFM/Evh/8Aax1rztbufEPwk1zX5Et7e+H7yztn
k2RyRf8APMDr5dAH7C0VHHIJUDrypqSgAoqvcSi3t5JJOkY3/JXxvqP/AAVP+F+mX9xayeE/HzzQ
SPGcaH3H/bSgD7Qor4o/4eu/C7/oUPiB/wCCP/7ZR/w9d+F3/QofED/wR/8A2ygD7Xor4o/4eu/C
7/oUPiB/4I//ALZR/wAPXfhd/wBCh8QP/BH/APbKAPteivij/h678Lv+hQ+IH/gj/wDtlfmjc/t0
/Fzwh8S/E2qeEfHetWejXerXNzb6bqMv2iONJJc7DHJny/06UAf0C0V+Pnw3/wCCz/jfQnS38ceE
dJ8TW44e60yQ2dx7cfvI6+9v2Zf22PCX7URaDQtC8S6VeRR+ZJ/aGnv9nx/18JmOgD6Nooqhq2pQ
aNpd3fTnFvbxvJJ+FAEt/qEGl2k91cuI7eFPMdz2FUPDPibTvFWkR6jpdybqyk5SUxPHn/vsA180
aN8cL3xX4vvY9d1H+zNF1CzuLe3j/wCWdv5n+r8ysfxb4on8I+GPDvh7QfEPm3On/aJLy502STy/
3n+roA+yK5258a6PZeJrfw7PeBNWuI/Mjttj8j/fxivi7/hYPin/AKGHU/8AwIkr07SPFGk3V5oP
jO78Q2/2nS9Lkt7ixl/4/ZLigD6lor5y+Anxq1XV9bTQNeuPtgnGYLqX/WeZ/wA869Q+LvxF/wCF
d+E3v4U829nk+z20b9DJQBueKvGOleELO3utYvDYwTyCBD5byfP6fJmt/hxXyTpnit/iV4Tl03xB
4kt7XVoNUjvUl1H/AFf2f/nnHWD8Q/ihq+qeM9Vn0bXb+LSvM/0fypPLoA+1q5/QfGOkeKZ9Qg06
7NxLp8v2e5AjdNknpzXx54c+J+u2PiPSrq/13UpbGO4jkuIjcf8ALOu11zxRb+BNH8Rz6F4kt7rU
dc1SO8t/7N/1kcf/AE0oA+rqK8w+BvxMm+I3hy4+3eUNWsJPKuPLHEg/gk/HFfGv/BTb9ubxJ8Gt
Xs/hx8P786Tr89p9s1LVUA8y3jfiNI/RzgnP0oA+0L34/eBLD4u2nwvuNcMPjm6tvtkelGyuP3kf
r5vl+X/4/XpNfj3p/wAXfBuua94d+Pd58UrJNc0v4fyaHeaJcSSf2zJrAtpbdPLH/TST975n1r43
/wCGnfi3/wBFK8Uf+DSWgD+iTx9480T4b+DtW8TeIr86boel2/2m7uvKeTyo/XZGC/6UeAPHuifE
rwbpPibw7fnU9C1S3+0Wl15Tx+bH67HAf9K/ET9nL4/ar40g+Ingb4lfEq+tbLxX4ck0vTtR8R3k
kllbXnmJJGX/AOeffmuz8f8A7Z/iD9nfU/hX4W+FfjqDxFYeEfD9vp+tpZHzNKv7jzPMk2bxzxx5
goA/bCivPfgZ8WNN+N/wl8M+OdJi8iDWLT7Qbd+sch4kTPs+a9CoAKKKKACvzu/4LLW/234afDG0
37PtHiMxfnFX6I1+ev8AwWH/AORF+Ev/AGNH/tOgDirL/gifoN1aW8//AAtS/wDnTf8A8geP/wCO
VN/w5D0H/oq+p/8Agnj/APjlfoP4q8Y23w5+Gd94nurW5vbPR9PN5JbWUfmySIkecRj6VzP7Pv7S
Xgr9pXwWPEfg+9MkcT+XeWVx8lxaSekif1oA+HR/wRI0KL/mq+of+CeP/wCOVBY/8EV/DWpwia2+
Lt5PbnpJBpccmf8AyLXT/tI/tKeMP2qPiNP8BfgJLvh/1fiLxdGSbaGLP7xEkHGzA/4H0Hc19lfs
6/BPSv2ePhLoXgbRp5ry3sFbfdXHD3ErnfI5/GgD4R/4Jd/D6L4S/tQfHjwZBfPqUWhxx6elzJHs
80R3Enz1gftcfs/QftM/8FJU8DXWryaBFceG47r7bFb/AGg/u4+nl16X+wr/AMn8ftS/9fn/ALcS
Voap/wAphdP/AOxT/wDadAHD/wDDkTQv+ir6h/4J4/8A45S/8ORNE/6KxqX/AIKI/wD45X2n+0b+
074X/Ze0rQ9W8XWupSaXqd59jNzp9v5iW3Gd8ldZrPxi8HaD8NH8f3XiC0Xwj9k+2DVFkzHJH2Ke
tAH57X//AARZ8NaXB5918Xry3j/56XGlxx/+1awPiX/wR60XwB8OvE/ieP4n6hfHR9OuNRjtv7Hj
j8zy4zJ/z19q6XR9N8bf8FRPilHrGqJf+E/2fNAvCLSyU+XJqciH1HHmdeefLz6191/tC2yaf+zr
8QreBfLjTw3exxj/ALd5KAPIf+CX3/JkvgD/AHr3/wBLJa/P79lf/gn/AKZ+11D4/wDEN541u/Dc
ml+I7iy+z21glwH/AOWm/wD1nviv0B/4Jff8mS+AP969/wDSyWvNf+CR3/IjfFn/ALHO4/8ARYoA
8/8A+HImhf8ARV9Q/wDBPH/8cpf+HImif9FY1L/wUR//AByvr7xR+2J4C8EftAWvwk1+S60bXbyC
OWz1C8jEdnOX+5GJKX9rD9rPwx+yv4EfVtUZNR1+8GzStFjf97dyevHRB60AfGs//BFvwvDex2kn
xgvI7uQZjgk0uLe//kWvCf2xf+Ce2m/sj+BdC8UWfje78RSXurR6f9nuNPjtxHkGTf8A6z/pn+tf
Xn7GP7Onj7xx8Sf+Gi/jTfXC+Kr2N/7E0N8p9jt5ARkpyU+Q/JH75NS/8Fjf+SCeDP8Asabf/wBF
SUAfdmkf8guz/wCuEf8AKrtUtI/5Bdn/ANcI/wCVXaACmeUn90U+igBnlJ/dFHlJ/dFPooAZ5Sf3
RR5Sf3RT6KAGeUn90V+ebf8ABIDwx4n+IfiLxP4x8c6nexapqlxqCadpFvHb7PMkMmwvJ5n0r9D6
KAPnn4afsEfAz4WLG+keANMvruP7t7rUf22Uf9/M175a2sGnwRw28KQQp8iIi4Aq1RQAVyXxW/5J
v4i/685K62uS+K3/ACTfxF/15yUAeCfD79nG08a+ENN1mTW7i3kvI/M8vyBXRf8ADJdp/wBDHc/+
Ag/xr0P4C/8AJKdB/wCuVeh0AfPP/DJdp/0Mdz/4CD/Gj/hku0/6GO5/8BB/jX0NRQB8waX8Novh
j8bvB9lHfSX/ANoEkvmSR+X/AM9K6j9qS1+1aZ4agz5fm3vl/pV3x9/ycN4F/wCveT/2pUX7Tf8A
x7+Ff+wh/SgDJT9ki0eP/kZZvxtP/tlJ/wAMl2n/AEMdz/4CD/GvoOP/AFa0+gD55/4ZLtP+hjuf
/AQf40f8Ml2n/Qx3P/gIP8a+hqKAPn/9nLRR4c8Z+ONNV/NFlJHb+b/f/eSV8M/tP/s62v7UP/BS
rVvBV1rcugo/h63vPtcNuLgny4+mw198/BL/AJKf8Sf+vz/2pJXzVp3/ACmGv/8AsUh/6LoA4f8A
4ciaF/0VfUP/AATx/wDxyl/4ciaJ/wBFY1L/AMFEf/xyvtH9o39qPwp+zBaeHr7xfaakdN1e7+x/
bbK38yO3OM5krq/E3xl8HeD/AIYyePtQ1+zXwklp9rTU4ZPMSWM/cMePv5oA/Pm//wCCLPhrTLfz
Ln4vXdvF/wA9J9Ljj/8Aatcx8Xf+CQmi/DH4W+K/F8HxL1C+l0PTLjUUtTpccfmeXGZNn+t9q7Dw
zofjX/gpx8TrfxX4hS78L/AXQLs/2ZpwzHJqciH26nr+8/gzX21+1OiW37MPxPjX7kfhu9j/AA8g
0Aeef8Ey/wDkyX4cf9c73/0tuK+o6+WP+CZP/Jknw1/653n/AKW3FfU9ABRRRQAV+ff/AAWD0ib/
AIVN8P8AXBH/AMS/TPE8TXkn9wPGcf8AoFfoJXIfEf4Z6B8WfBWqeFPE1gmo6LqUflzwPwfZwccO
DQBf8IaxYeJ/B+k6lYXEF7pt5aRyRyxfPHJGUr4S+Pv/AATj8VH4h6l4i+AvitPAtn4ojks/EWl/
aJIbcRyf6ySPy+3/AEz/ACxzT7L/AIJw/Fv4bxz6T8Mf2jNc8L+FxJ5kGnPHL+7Pp8kn9BVn/hh7
9qL/AKOw1f8A793H/wAcoA+ov2a/2afCn7MPgCHw54ah824lxJqGqzD/AEi/n/56Sf4V6zJOkEbv
I4RE+879K+BP+GHv2ov+jsNX/wC/dx/8cqtqP/BPv4+eLrOTS/F/7T+tap4euPku7SOOf97H6YMu
KAK3/BPi8j8VftfftM+KtKcXvh661COK2vYx+7k/fyn5PwFSePdYtvBH/BXLwrqWsyHT7LWPDf2O
zuJOI5JDHLGB/wB/K+u/2e/2efCn7Nvw+t/CfhOB1t9/n3N5ccz3c/8Az0k/KuY/al/ZI8IftU+G
LSy1uS40nXdNfzNM1yx/4+LU+n+2nt689aAPVfiD8P8AQPip4Tv/AAz4m0+HVdGvk8u4tpO9fnnp
X/BLvxjN44t/BmueP5774A6ffyapa6J9okFw5J/1Xl9Aefv11lr+wj+0ppsCWun/ALVWsw2cH7uC
OSO44j/7+1L/AMMPftRf9HYav/37uP8A45QB90eF/Cuk+CdAsND0LT4NM0mwiEFvZ2ybI4k9AK8z
/a38U6X4K/Zs+Il9qdzHZWraJcWyPJ/HJJGUjQfUkV8x/wDDD37UX/R2Gr/9+7j/AOOUy3/4Jo+N
fiJq+nv8avjlrnxE0SxfzItIXzIxJ7EvIcfWgD1r/gmfp91YfsWeAY7uN7d5Eu5IhJ/zze6lKH8s
V47/AMEp9cg0G++NXgHUT9k8Taf4puLySyl/1gj/ANWf/H0r730Dw/YeFtEstJ0u3jstNsYEt7e3
j4SONOAB+FfKP7RX7AFn8VfiIvxI8A+LL74Z/EEHM+oadxHcEf8ALSTZg78Y6Hn8KAPSP2sv2TPD
H7VHgV9M1JRpviGz+fSddjX95aSde3VD3FfPf7NH/BPHxJp/xEj8ffHnxCnjrXtIRLbQ7SSeS5gi
jjwI5JDJ/wCi+gpv/DD37UX/AEdhq/8A37uP/jlH/DD37UX/AEdhq/8A37uP/jlAH6A1+e3/AAV8
1a11DwD8OfB9vPG/iDVPEcUttZJ/rJUAMf8A6HIKsf8ADD37UX/R2Gr/APfu4/8Ajldp8CP+Ce0X
gT4mRfEr4l+NdR+KHjW35tZ9RyYLd/8AnoA+ST/KgD7A06N47C2jf76RpmrtFFABRRRQAUUUUAFF
FFABRRRQAUUUUAFcr8TLdrn4f+II408yQ2cmB+FdVTeHFAHmn7Pd/bX/AMLNJSGTzJLceXKP7j16
bXjOq/s/3Fhq9zf+EPEt34a+0f6y2i/1dVf+FQfEX/opV5/4/QB7hRXh/wDwqD4i/wDRSrz/AMfo
/wCFPfEP/opV7+b/AONADPGF1Hqv7R3hOC0cyyWdtJ9o8v8A5Z/6ypP2n0ePSPDt7/y72+oAyS/8
8/eut+G/wgsfAElxfPcyarrNx/rb246mus8SeHLDxZo9xpWpQfaLK4GJFJoAtWd1FqFnBPA/mRSJ
vSRO9XK8Mi+BPijQc2nh/wAe3lhpw/1dt/zzp/8AwqD4i/8ARSrz/wAfoA9wpjyCJdzcCvEv+FQf
EX/opV5/4/UUvwP8Z6pH9l1X4h3l3p8nEkQ35f8AWgB3wDlTVPHfxB1K3/eWVxefu5f7/wC8kr5l
1vVLbwf/AMFerO51iQ6db634YS2sJH/1dxJ5f/2s190+C/BuneA9Fi0vTY9lsnzvI/35H9TXkf7V
H7IHhT9qnQLKPVZ59F8RaZl9N16xH+kW/qh/voc9KAPT/iN8M/Dvxc8G6j4W8V6bDq2jahH5ctvL
9OHQ/wADgnqP8a/P7w9/wS88Xz+PLPwj4o8fT6t8BtIvn1Cw0UTyfaJDIf8AVvH0jPX5+e9dfD+w
r+0rZRpBZ/tV61HZx/u0jkjnyE/7+07/AIYe/ai/6Ow1f/v3cf8AxygD7q8OeG9M8JaHZ6No9hBp
2lWcfk29rbJsjij9AK8f/ba8V6V4M/ZX+JN3qd1HbRXOj3FlAJP+WlxJGUjQfU186/8ADD37UX/R
2Gr/APfu4/8AjlNs/wDgml4x+IWuafcfG742a18R9EsJPMj0j97HG/tl5DigD2L/AIJt6dcaX+xf
8NoruJkd7e4lXzP+eb3MrofyIr6hrN0jRbTQNKtNN062js9PtI0ggt4hhI406AfhWlQAUUUUAFFF
FABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUU
AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB/9lQSwMEFAAGAAgA
AAAhAJEtaklYBgAADxoAABoAAABjbGlwYm9hcmQvdGhlbWUvdGhlbWUxLnhtbOxZS28bNxC+F+h/
WOy9sd6KjciBrUfcxE6CSEmRI6WldhlzlwuSsqNbkZx6KVAgLXpogN56KIoGaIAGvfTHGHDQpj+i
Q+5DpETFD7hAUMQCjN3Zb4bDmdlvSO6Nm09j6h1hLghLOn71WsX3cDJhAUnCjv9wNPjsuu8JiZIA
UZbgjj/Hwr+5/eknN9DWhJJ0zBAPRhGOsQeGErGFOn4kZbq1sSEmIEbiGktxAs+mjMdIwi0PNwKO
jmGAmG7UKpXWRoxI4m+DRakM9Sn8S6RQggnlQ2UGewmKYfR70ymZYI0NDqsKIeaiS7l3hGjHB5sB
Ox7hp9L3KBISHnT8iv7zN7ZvbKCtXInKNbqG3kD/5Xq5QnBY02PycFwO2mg0G62d0r4GULmK67f7
rX6rtKcBaDKBmWa+mDabu5u7vWaONUDZpcN2r92rVy28Yb++4vNOU/0svAZl9hsr+MGgC1G08BqU
4Zsr+EajXes2LLwGZfjWCr5d2ek12hZegyJKksMVdKXZqneL2ZaQKaN7TvhmszFo13LjCxRUQ1ld
aogpS+S6WovRE8YHAFBAiiRJPDlP8RRNoCa7iJIxJ94+CSMovBQlTIC4UqsMKnX4r34NfaUjgrYw
MrSVX+CJWBEpfzwx4SSVHf82WPUNyOmbNyfPXp88+/3k+fOTZ7/mY2tTlt4eSkJT791P3/zz8kvv
799+fPfi22zoZbww8W9/+ertH3++zzzMeBGK0+9evX396vT7r//6+YXD+g5HYxM+IjEW3l187D1g
MUzQ4T8e84tpjCJETI2dJBQoQWoUh/2+jCz03TmiyIHbxXYcH3GgGhfw1uyJ5fAw4jNJHBbvRLEF
PGCM7jLujMIdNZYR5tEsCd2D85mJe4DQkWvsLkqsLPdnKXAscZnsRthy8z5FiUQhTrD01DN2iLFj
do8JseJ6QCacCTaV3mPi7SLiDMmIjK1qWijtkRjyMnc5CPm2YnPwyNtl1DXrHj6ykfBuIOpwfoSp
FcZbaCZR7DI5QjE1A76PZORycjjnExPXFxIyHWLKvH6AhXDp3OMwXyPpd4Bm3Gk/oPPYRnJJDl02
9xFjJrLHDrsRilMXdkiSyMR+Lg6hRJF3n0kX/IDZb4i6hzygZG26HxFspftsNngIDGu6tCgQ9WTG
Hbm8hZlVv8M5nSKsqQYagMXrMUnOJPklem/+d/QOJHr6w0vHjK6G0t2GrXxckMx3OHG+TXtLFL4O
t0zcXcYD8uHzdg/NkvsYXpXV5vWRtj/Stv+/p+117/PVk/WCn4G61bI1W67rxXu8du0+JZQO5Zzi
faGX7wK6UjAAodLTe1Rc7uXSCC7VmwwDWLiQI63jcSa/IDIaRiiFNX7VV0ZCkZsOhZcyAUt/LXba
Vng6iw9YkG1Zq1W1Pc3IQyC5kFeapRy2GzJDt9qLbVhpXnsb6u1y4YDSvYgTxmC2E3WHE+1CqIKk
N+cQNIcTemZX4sWmw4vrynyRqhUvwLUyK7Bs8mCx1fGbDVABJdhVIYoDlacs1UV2dTKvMtPrgmlV
AKwhigpYZHpT+bp2emp2WamdI9OWE0a52U7oyOgeJiIU4Lw6lfQ8blw015uLlFruqVDo8aC0Fm60
r7/Pi8vmGvSWuYEmJlPQxDvu+K16E0pmgtKOP4WtP1zGKdSOUMtdREM4NJtInr3wl2GWlAvZQyLK
Aq5JJ2ODmEjMPUrijq+mX6aBJppDtG/VGhDCB+vcJtDKh+YcJN1OMp5O8USaaTckKtLZLTB8xhXO
p1r98mClyWaQ7mEUHHtjOuMPEJRYs11VAQyIgBOgahbNgMCRZklki/pbakw57ZpnirqGMjmiaYTy
jmKSeQbXVF66o+/KGBh3+ZwhoEZI8kY4DlWDNYNqddOya2Q+rO26ZyupyBmkueiZFquorulmMWuE
og0sxfJyTd7wqggxcJrZ4TPqXqbczYLrltYJZZeAgJfxc3TdczQEw7XFYJZryuNVGlacnUvt3lFM
8AzXztMkDNZvFWaX4lb2COdwILxU5we95aoF0bRYV+pIuz5PHKDUG4fVjg+fCOBs4ilcwUcGH2Q1
JaspGVzBlwNoF9lxf8fPLwoJPM8kJaZeSOoFplFIGoWkWUiahaRVSFq+p8/F4VuMOhL3veLYG3pY
fkyery3sbzjb/wIAAP//AwBQSwMEFAAGAAgAAAAhAJStDd/UAAAArAEAACoAAABjbGlwYm9hcmQv
ZHJhd2luZ3MvX3JlbHMvZHJhd2luZzEueG1sLnJlbHOskL9qAzEMh/dC38For3WXIZQSX5YSyBqS
BxC2zuf0/AfbCc3b122WHgS6dBFIQp8+fpvtp5/FlXNxMSjoZQeCg47GBavgdNy9vIIolYKhOQZW
cOMC2+H5aXPgmWo7KpNLRTRKKAqmWtMbYtETeyoyJg5tM8bsqbY2W0ykP8gyrrpujfk3A4YFU+yN
grw3KxDHW2qf/2bHcXSa36O+eA71wQuszYsbkLLlqkDK++Ree9lcAR9r9P+p4XyLYKHh2TjCn3kv
z4nttwcuMh6+AAAA//8DAFBLAQItABQABgAIAAAAIQDI4TOSFQEAAFICAAATAAAAAAAAAAAAAAAA
AAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAK0wP/HBAAAAMgEAAAsAAAAA
AAAAAAAAAAAARgEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhADLup0Y9BgAAxR8AAB8AAAAA
AAAAAAAAAAAAMAIAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWxQSwECLQAKAAAAAAAA
ACEAmVsoI3kYAAB5GAAAGwAAAAAAAAAAAAAAAACqCAAAY2xpcGJvYXJkL21lZGlhL2ltYWdlMS5q
cGVnUEsBAi0AFAAGAAgAAAAhAJEtaklYBgAADxoAABoAAAAAAAAAAAAAAAAAXCEAAGNsaXBib2Fy
ZC90aGVtZS90aGVtZTEueG1sUEsBAi0AFAAGAAgAAAAhAJStDd/UAAAArAEAACoAAAAAAAAAAAAA
AAAA7CcAAGNsaXBib2FyZC9kcmF3aW5ncy9fcmVscy9kcmF3aW5nMS54bWwucmVsc1BLBQYAAAAA
BgAGALABAAAIKQAAAAA=
">
  <v:shapetype id="_x0000_t75" coordsize="21600,21600" o:spt="75"
   o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
   <v:stroke joinstyle="miter"/>
   <v:formulas>
    <v:f eqn="if lineDrawn pixelLineWidth 0"/>
    <v:f eqn="sum @0 1 0"/>
    <v:f eqn="sum 0 0 @1"/>
    <v:f eqn="prod @2 1 2"/>
    <v:f eqn="prod @3 21600 pixelWidth"/>
    <v:f eqn="prod @3 21600 pixelHeight"/>
    <v:f eqn="sum @0 0 1"/>
    <v:f eqn="prod @6 1 2"/>
    <v:f eqn="prod @7 21600 pixelWidth"/>
    <v:f eqn="sum @8 21600 0"/>
    <v:f eqn="prod @7 21600 pixelHeight"/>
    <v:f eqn="sum @10 21600 0"/>
   </v:formulas>
   <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
   <o:lock v:ext="edit" aspectratio="t"/>
  </v:shapetype><v:shape id="Picture_x0020_13" o:spid="_x0000_s1027" type="#_x0000_t75"
   style='position:absolute;left:2509;top:381;width:4896;height:630;
   visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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">
   <v:imagedata src="file:///C:/Users/alrasha1/AppData/Local/Temp/9/msohtmlclip1/01/clip_image001.jpg"
    o:title=""/>
  </v:shape><v:rect id="Rectangle_x0020_14" o:spid="_x0000_s1028" style='position:absolute;
   left:2716;top:964;width:1833;height:829;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" strokecolor="white"/>
  <v:rect id="Rectangle_x0020_15" o:spid="_x0000_s1029" style='position:absolute;
   left:5073;top:973;width:3108;height:969;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQDtm/EfxAAAANsAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9BawIx
FITvQv9DeAUvotmqVFmNUgRB0Eu1iMfH5rnZdvOybOK6+uuNUPA4zMw3zHzZ2lI0VPvCsYKPQQKC
OHO64FzBz2Hdn4LwAVlj6ZgU3MjDcvHWmWOq3ZW/qdmHXEQI+xQVmBCqVEqfGbLoB64ijt7Z1RZD
lHUudY3XCLelHCbJp7RYcFwwWNHKUPa3v1gFvw3lvOsdjmZSbm/+NNrce9VJqe57+zUDEagNr/B/
e6MVjEfw/BJ/gFw8AAAA//8DAFBLAQItABQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAAAAAAAAA
AAAAAAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsA
AAAAAAAAAAAAAAAAHwEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhAO2b8R/EAAAA2wAAAA8A
AAAAAAAAAAAAAAAABwIAAGRycy9kb3ducmV2LnhtbFBLBQYAAAAAAwADALcAAAD4AgAAAAA=
" filled="f" strokecolor="white"/>
  <v:shapetype id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
   <v:stroke joinstyle="miter"/>
   <v:path gradientshapeok="t" o:connecttype="rect"/>
  </v:shapetype><v:shape id="Text_x0020_Box_x0020_16" o:spid="_x0000_s1030"
   type="#_x0000_t202" style='position:absolute;left:3164;top:1064;width:962;
   height:492;visibility:visible;mso-wrap-style:square;v-text-anchor:top'
   o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
   <v:textbox inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal style='margin-right:.1pt;line-height:106%'><b
      style='mso-bidi-font-weight:normal'><span style='font-size:10.5pt;
      mso-bidi-font-size:11.0pt;line-height:106%'>1 injection per month<o:p></o:p></span></b></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><v:shape id="Text_x0020_Box_x0020_17" o:spid="_x0000_s1031" type="#_x0000_t202"
   style='position:absolute;left:5300;top:1073;width:2675;height:756;
   visibility:visible;mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
   <v:textbox inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal style='margin-top:0in;margin-right:20.1pt;margin-bottom:
      0in;margin-left:19.9pt;margin-bottom:.0001pt;text-indent:23.0pt;
      line-height:107%'><b style='mso-bidi-font-weight:normal'><span
      style='font-size:10.5pt;mso-bidi-font-size:11.0pt;line-height:107%'>1
      injection every 3 months or as<o:p></o:p></span></b></p>
      <p class=MsoNormal style='margin-top:.45pt'><b style='mso-bidi-font-weight:
      normal'><span style='font-size:10.5pt;mso-bidi-font-size:11.0pt'>recommended
      by your doctor<o:p></o:p></span></b></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><w:wrap type="topAndBottom" anchorx="page"/>
 </v:group><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="379" height="105" src="file:///C:/Users/alrasha1/AppData/Local/Temp/9/msohtmlclip1/01/clip_image002.png" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--><br /><strong>3 months</strong></p><p>&nbsp;</p><p>Method of administration</p><p>Beovu is given as an injection into your eye (intravitreal use) by an eye doctor.</p><p>&nbsp;</p><p>Before the injection, your doctor will clean your eye carefully, to prevent infection. Your doctor will also give you an eye drop (local anaesthetic) to numb the eye to reduce or prevent pain from the injection.</p><p>&nbsp;</p><p>How long does Beovu treatment last for</p><p>Wet AMD is a chronic disease and it therefore needs long-term treatment with this medicine, possibly continuing for months or years. Your doctor will check that the treatment is working during your regular scheduled visits. Your doctor may also check on your eyes between injections. If you have questions about how long you will receive Beovu, talk to your doctor.</p><p>&nbsp;</p><p>a. If you stop using Beovu</p><p>Speak with your doctor before stopping treatment. Stopping treatment may increase your risk of vision loss and your vision may worsen.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. The side effects with Beovu injection are either from the medicine itself or from the injection procedure and they mostly affect the eye.</p><p>&nbsp;</p><p>Some side effects could be serious</p><p>Get immediate medical help if you have any of the following, which are signs of allergic reactions, inflammations or infections:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a sudden decrease or change in vision</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain, increased discomfort, worsening eye redness</p><p>If you have any serious side effects, <strong>tell your doctor immediately. Other possible side effects</strong></p><p>Other side effects which may occur after Beovu treatment include those listed below.</p><p>&nbsp;</p><p>Most of the side effects are mild to moderate and will generally disappear within a week after each injection.</p><p>&nbsp;</p><p>If these side effects become severe, please tell your doctor.</p><p>&nbsp;</p><p><strong>Common: </strong><em>may affect up to 1 in every 10 people</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the middle layer of the eye wall (uveitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; detachment of the gel-like substance inside the eye (vitreous detachment)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tearing of the retina (the part at the back of the eye that detects light) or one of its layers (retinal pigment epithelial tear)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduced sharpness of vision (reduced visual acuity)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding in the retina (retinal haemorrhage)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the iris, the coloured part of the eye (iritis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; clouding of the lens of the eye (cataract)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding from small blood vessels in the outer layer of the eye (conjunctival haemorrhage)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; moving spots in your vision (vitreous floaters)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; eye pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase in pressure inside the eye (intraocular pressure increase)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; redness in the white of the eye (conjunctivitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blurred or unclear vision</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; scratched cornea, damage to the clear layer of the eyeball that covers the iris (corneal abrasion)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; damage to the clear layer of the eyeball that covers the iris (punctuate keratitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reactions (hypersensitivity)</p><p>&nbsp;</p><p><strong>Uncommon: </strong><em>may affect up to 1 in every 100 people</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe inflammation inside the eye (endophthalmitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blindness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden vision loss due to blockage of an artery in the eye (retinal artery occlusion)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; detachment of the retina (retinal detachment)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; redness of the eye (conjunctival hyperaemia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased tear production (lacrimation increased)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal feeling in the eye</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; detachment of one of the layers of the retina (detachment of retinal pigment epithelium)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the gel-like substance inside the eye (vitritis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the front of the eye (anterior chamber inflammation or flare)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation in the iris and its adjacent tissue in the eye (iridocyclitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the cornea, the clear layer of the eyeball (corneal oedema)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding in the eye (vitreous haemorrhage)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden vision loss due to blockage of blood vessels in the back of the eye (retinal vascular occlusion)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of blood vessels in the back of the eye (retinal vasculitis)</p><p>&nbsp;</p><p>&nbsp;</p><p>Reporting of side effects</p><p>If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong><u>Pre-filled syringe</u></strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date which is stated on the carton and label after EXP. The expiry date refers to the last day of that month.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store in refrigerator (2&deg;C &ndash; 8&deg;C). Do not freeze</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep the pre-filled syringe in the sealed blister and in the outer carton in order to protect from light.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prior to use, the unopened blister with the pre-filled syringe may be kept at room temperature (below 30&deg;C) for up to 24 hours.</p><p>&nbsp;</p><p><strong><u>Vial</u></strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date which is stated on the carton and label after EXP. The expiry date refers to the last day of that month.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store in refrigerator (2&deg;C &ndash; 8&deg;C). Do not freeze</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep the vial in the outer carton in order to protect from light.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prior to use, the unopened vial may be kept at room temperature (below 30&deg;C) for up to 24 hours.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong><u>Pre-filled syringe</u></strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is brolucizumab. One ml solution for injection contains 120 mg brolucizumab. Each pre-filled syringe contains 19.8 mg brolucizumab in 0.165 ml solution. This provides a usable amount to deliver a single dose of 0.05 ml solution containing 6 mg of brolucizumab.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are: sodium citrate, sucrose, polysorbate 80, water for injections.</p><p>&nbsp;</p><p><strong><u>Vial</u></strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is brolucizumab. One ml solution for injection contains 120 mg brolucizumab.Each vial contains 27.6 mg brolucizumab in 0.23 ml solution. This provides a usable amount to deliver a single dose of 0.05 ml solution containing 6 mg of brolucizumab.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are: sodium citrate, sucrose, polysorbate 80, water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Beovu 120 mg/ml solution for injection vial or in a pre-filled syringe (injection) is a clear to slightly opalescent, colourless to slightly brownish-yellow aqueous solution.

•	Pack size of 1 pre-filled syringe for single use only.
•	Pack size of 1 vial and 1 blunt filter needle (18G x 1½″, 1.2 mm x 40 mm, 5 μm) for single use only.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorization Holder for this Product is Novartis Europharm Limited, Irelandwww.Novartis.com</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Manufacturers;</p><p>o <u>Pre-filled syringe: </u>Manufactured by Alcon-Couvreur, Puurs, Belgium</p><p>o <u>Vial: </u>Manufactured by Novartis Pharma AG, Stein, Switzerland</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                approved by EMA in 11/2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ما هو عقار بيوفيو؟</p><p dir="RTL">يحتوي عقار بيوفيو على المادة الفعّالة برولوسيزوماب، التي تنتمي إلى مجموعة من الأدوية تُسمى مضادات التَّوَعٍّي الحَديثُ. يُحقَن عقار بيوفيو في العين بمعرفة طبيبك لعلاج اضطراب في العين يُسمى التنكُّس البقعي حَديث التَّوَعِّي (الرطب) المرتبط بالسن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600"
 o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f"
 stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_1" o:spid="_x0000_i1025" type="#_x0000_t75"
 style='width:233.25pt;height:122.25pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/alrasha1/AppData/Local/Temp/9/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="311" height="163" src="file:///C:/Users/alrasha1/AppData/Local/Temp/9/msohtmlclip1/01/clip_image002.jpg" /></p><p dir="RTL">&nbsp;</p><p dir="RTL">فيم يُستخدم عقار بيوفيو؟</p><p dir="RTL">يُستَخدَم عقار بيوفيو لعلاج التنكُّس البقعي حَديث التَّوَعِّي الرطب المرتبط بالسن في البالغين، وهي حالة تحدث عندما تتشكل أوعية دموية غير طبيعية وتنمو أسفل بقعة الشبكية. بقعة الشبكية -التي تتواجد في الجزء الخلفي من العين- هي المسؤولة عن وضوح الرؤية. قد تسرّب الأوعية الدَّموية غير الطبيعية السائل أو الدَّم في العين وتتداخل مع وظائف بقعة الشبكية، الأمر الذي يُؤدي إلى قصور في الرؤية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">كيفية عمل عقار بيوفيو</p><p dir="RTL">تُسبب مادة تُسمى عامل نمو بطانة الأوعية الدموية &quot;أ&quot; (VEGF‑A) نمو الأوعية الدَّموية في العين. يمنع عقار بيوفيو تأثير المادة المُسمّاة بعامل نمو بطانة الأوعية الدَّموية &quot;أ&quot; عن طريق الارتباط بها، وبالتَّالي يقلل من نمو الأوعية الدَّموية غير الطبيعية في حالات التنكُّس البقعي المرتبط بالسن، وهذا بدوره يقلل من تسرُّب السائل أو الدَّم في العين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يُبطئ عقار بيوفيو تطور المرض وبالتَّالي يحافظ على رؤيتك، بل ويحسّنها.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&zwnj;أ.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>يجب ألا يتم إعطاؤك عقار بيوفيو في الحالات الآتية</strong><strong>:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه برولوسيزوماب أو تجاه أي من المكونات الأخرى بهذا الدَّواء (المدرجة في قسم: 6).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مُصابًا بعدوى نشطة أو يُشتَبَه في إصابتك بعدوى في العين أو حولها.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تُعاني من ألم أو احمرار في عينك (التهاب العين).</p><p dir="RTL">إذا انطبق عليك أي من هذه الحالات، فأخبر طبيبك. فيجب تجنُّب إعطاء عقار بيوفيو لك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&zwnj;ب.&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">تحدَّث إلى طبيبك قبل إعطائك عقار بيوفيو إذا كان ينطبق عليك أي مما يلي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مُصابًا بالجلوكوما (حالة تصيب العين تنجم عادةً عن ارتفاع الضغط في العين).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك تاريخ مرضي من رؤية ومضات ضوء أو عوائم (بقع عائمة مظلمة) وإذا حدثت لديك زيادة مفاجئة في حجم العوائم وعددها.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد خضعت لجراحة في العين في الأسابيع الأربعة الماضية أو إذا كان من المقرر لك إجراء جراحة في العين في الأسابيع الأربعة القادمة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد أُصِبت من قبل بأية أمراض في العين أو تلقيت علاجات في العين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك تاريخ مرضي من فقدان الرؤية المفاجئ بسبب انسداد الأوعية الدموية في الجزء الخلفي من العين (انسداد الأوعية الدموية في شبكية العين) أو التهاب الأوعية الدموية في الجزء الخلفي من العين (التهاب الأوعية الدموية في شبكية العين) في العام الماضي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أخبر طبيبك على الفور </strong>في الحالات الآتية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عند احمرار العين أو ألم بالعين أو شعور متزايد بعدم الراحة أو تفاقم احمرار العين أو عدم وضوح الرؤية أو قصورها أو ارتفاع عدد الجسيمات الصغيرة في مجال رؤيتك أو زيادة الحساسية تجاه الضوء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أُصِبت بفقدان مفاجئ للرؤية، وهو ما قد يكون علامة على التعرُّض لانسداد الأوعية الدموية في الشبكية.</p><p dir="RTL">قد يؤدي أي من الأعراض المذكورة أعلاه إلى توقف طبيبك عن علاجك بـ عقار بيوفيو.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">علاوة على ذلك، من المُهِم بالنسبة لك معرفة الآتي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لم يخضع أمان وفعَّالية عقار بيوفيو عند إعطائه في كلتا العينين بالتَّزامن للدراسة، واستخدامه بهذه الطريقة قد يُؤدي إلى زيادة خطر الإصابة بآثار جانبية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يُسبب حَقْن عقار بيوفيو ارتفاعًا في ضغط العين (الضغط داخل العين) لدى بعض المرضى في غضون 30 دقيقة من الحَقْن. سيراقب طبيبك هذا الأمر بعد كل عملية حَقْن.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيتحقق طبيبك مما إذا كان لديك عوامل خطورة أخرى قد تُزيد من فرص حدوث تمزُّق أو انفصال لإحدى الطبقات الموجودة في الجزء الخلفي من العين (انفصال الشبكية أو تمزُّقها وانفصال الظهارة الصبغية للشبكية أو تمزُّقها) أم لا، في هذه الحالة يجب إعطاء عقار بيوفيو بحذر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يرتبط الاستخدام الجهازي لمثبطات عامل نمو بطانة الأوعية الدموية، وهي مواد مماثلة لتلك الموجودة في عقار بيوفيو، بخطر تكوّن جلطات دموية سادّة للأوعية الدموية (أحداث الانصمام الخثاري الشرياني)، والتي قد تؤدي إلى الإصابة بنوبة قلبية أو سكتة دماغية. هناك خطر من النَّاحية النَّظرية لوقوع هذه الأحداث بعد حقن عقار بيوفيو في العين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا يُستَخدَم عقار بيوفيو في الأطفال والمراهقين؛ لأن التنكُّس البقعي الرطب المرتبط بالسن يحدث في البالغين فقط.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&zwnj;ج.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>استخدام أدوية أخرى مع عقار بيوفيو</strong></p><p dir="RTL">أخبر طبيبك إذا كنت تستخدم أو استخدمت مؤخرًا أو قد تستخدم أيَّة أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&zwnj;د.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">إذا كنتِ حاملًا أو مرضعًا، أو تعتقدين أنكِ قد تكونين حاملًا أو تخططين لذلك، فاستشيري طبيبك قبل إعطاء هذا الدَّواء لكِ.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُوصى بتجنُّب الرضاعة الطبيعيَّة أثناء العلاج بعقار بيوفيو ولمدة شهر واحد على الأقل بعد إيقاف العلاج بعقار بيوفيو؛ ذلك لأنه من غير المعروف مما إذا كان عقار بيوفيو يمر في لبن الأم أم لا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب على السيدات اللاتي لديهن القدرة على الحَمْل استخدام وسيلة فعَّالة لمنع الحَمْل أثناء العلاج ولمدة شهر واحد على الأقل بعد التوقف عن العلاج بعقار بيوفيو. إذا أصبحتِ حاملًا أو كنتِ تعتقدين أنكِ حامل أثناء العلاج، فأخبِري طبيبكِ فورًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&zwnj;ه.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">بعد حَقْنك بعقار بيوفيو، قد تُصاب بمشاكل مؤقتة في الرؤية (على سبيل المثال: عدم وضوح الرؤية). لا تقم بممارسة القيادة أو استخدام الآلات طالما استمرت هذه المشاكل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&zwnj;و.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>معلومات مهمة عن محتويات عقار ببيوفيو</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>-</strong><strong>يحتوي عقار بيوفيو على الصوديوم</strong></p><p dir="RTL">يحتوي الدَّواء على أقل من 1 مللي مول من الصوديوم (23 مجم) لكل الجرعة، أي يُمكِن القول أنه &quot;خالي من الصوديوم&quot; بشكل أساسي.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما الكمية التي يتم إعطاؤها من عقار بيوفيو؟ وما هو عدد مرات إعطائه؟</strong></p><p dir="RTL">الجرعة الموصى بها هي 6 مجم من برولوسيزوماب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيتم علاجك بعملية حَقْن واحدة كل شهر خلال أول 3 أشهر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعد ذلك، قد تتلقى عملية حَقْن واحدة كل 3 أشهر. سيحدد طبيبك الفاصل الزمني لعلاجك بناءً على حالة عينك، قد يحتاج بعض المرضى إلى تلقي العلاج كل شهرين. يجب ألا تقل فترة العلاج بين جرعتين من عقار ببيوفيو عن شهرين .</p><p dir="RTL">&nbsp;</p><p dir="RTL"><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_1" o:spid="_x0000_i1025" type="#_x0000_t75"
 style='width:228pt;height:89.25pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/alrasha1/AppData/Local/Temp/9/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="304" height="119" src="file:///C:/Users/alrasha1/AppData/Local/Temp/9/msohtmlclip1/01/clip_image002.jpg" /></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>طريقة الإعطاء</strong></p><p dir="RTL">يُعطى عقار بيوفيو في هيئة حَقْن داخل عينك (للاستخدام داخل الجسم الزجاجي للعين) بمعرفة أحد أطباء العيون.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قبل الحَقْن، سيقوم طبيبك بتنظيف عينك بعناية، لمنع حدوث عدوى. سيعطيك طبيبك أيضًا قطرة في العين (كتخدير موضعي) لتخدير العين؛ وذلك لتقليل أو منع الألم الناتج عن الحَقْن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كم تستمر مدة العلاج بعقار بيوفيو؟</strong></p><p dir="RTL">التنكُّس البقعي الرطب المرتبط بالسن هو أحد الأمراض المزمنة ولذلك يحتاج إلى العلاج طويل الأمد باستخدام هذا الدَّواء، ربما يستمر لأشهر أو أعوام. سيتحقق طبيبك من فعالية العلاج أثناء زياراتك المُقَررة المُعتادة. قد يفحص طبيبك عينيك أيضًا في الفترة بين عمليات الحَقْن. إذا كانت لديك أسئلة حول المدة التي ستتلقى خلالها عقار بيوفيو، فيُرجى التَّحدث إلى طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&zwnj;أ.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>قبل التوقف عن العلاج بعقار بيوفيو</strong></p><p dir="RTL">تحدَّث مع طبيبك قبل التَّوقف عن تلقي العلاج. قد يُؤدي إيقاف العلاج إلى زيادة خطر تعرضك لفقدان الرؤية كما قد تسوء رؤيتك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">اسأل طبيبك في حالة وجود أية أسئلة إضافية متعلقة باستخدام هذا الدَّواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل كافة الأدوية، قد يُسبب هذا الدَّواء آثارًا جانبية، على الرَّغم من عدم حدوثها لدى الجميع. تنتج الآثار الجانبية المصاحبة لحقن عقار بيوفيو إما من الدَّواء نفسه أو من إجراء الحَقْن وفي غالب الأحيان تُؤثر على العين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بعض الآثار الجانبية التي قد تكون خطيرة</p><p dir="RTL">احصل على المساعدة الطبية الفورية إذا أُصِبت بأيٍّ مما يلي، وهي علامات الإصابة بتفاعلات الحساسية أو حالات الالتهاب أو العدوى:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قصور مفاجئ أو تغيُّر في الرؤية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم، شعور متزايد بعدم الراحة، تفاقم احمرار العين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا أُصِبت بأيَّة آثار جانبية خطيرة،<strong> فأخبر طبيبك فورًا</strong><strong>.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية المحتملة الأخرى</strong></p><p dir="RTL">تتضمن الآثار الجانبية الأخرى التي قد تحدث بعد العلاج بعقار بيوفيو تلك المُدرَجة أدناه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">غالبية الآثار الجانبية تكون طفيفة إلى معتدلة وستزول بشكل عام في غضون أسبوع بعد كل عملية حَقْن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا أصبحت هذه الآثار الجانبية شديدة، يُرجى إخبار طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة</strong><strong>: </strong><em>قد تُؤثر على ما يصل إلى شخص واحد من بين كل </em><em>10&nbsp;</em><em>أشخاص</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الطبقة الوسطى من جدار العين (الْتِهاب العِنَبِيَّة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انفصال المادة التي تشبه الهلام داخل العين (انفصال الجسم الزجاجي للعين).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تمزُّق الشبكية (الجزء الموجود بالجزء الخلفي للعين الذي يعمل على استكشاف الضوء) أو أحد طبقاتها (تمزُّق الظهارة الصبغية للشبكية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض حدة الإبصار.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف في الشبكية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب القزحية، وهي الجزء الملون من العين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إعتمام عدسة العين (المياه البيضاء).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف من الأوعية الدَّموية الصغيرة الموجودة في الجزء الخارجي من العين (نزيف بالملتحمة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بقع متحركة في مجال الرؤية لديك (عوائم بالجسم الزجاجي للعين).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالعين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع الضغط داخل العين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار في بياض العين (التهاب المُلْتَحِمَة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضبابية الرؤية أو عدم وضوحها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خدش بالقرنية، تلف بالطبقة الشفافة لمقلة العين التي تغطي القُزَحِيَّة (سحج القرنية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تلف بالطبقة الشفافة لمقلة العين والتي تغطي القُزَحِيَّة (الْتِهاب القَرْنِيَّةِ المنقط).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية (فرط الحساسية).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة</strong><strong>:</strong><em> قد تُؤثر على ما يصل إلى شخص واحد من بين كل </em><em>100&nbsp;</em><em>شخص</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب شديد داخل العين (التهاب باطن المقلة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان البصر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان مفاجئ للرؤية نتيجة انسداد أحد الشرايين في العين (انسداد الشريان الشبكي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انفصال الشبكية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار العين (تَـبَيُّغ [احتقان] الملتحمة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة إفراز الدموع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إحساس غير طبيعي في العين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انفصال إحدى طبقات الشبكية (انفصال الظهارة الصبغية للشبكية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المادة التي تشبه الهلام داخل العين (التهاب الجسم الزجاجي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الجزء الأمامي من العين (التهاب الغرفة الأمامية أو احتدامها).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب القُزَحِيَّة والنَّسيج المجاور لها في العين (الْتِهاب القُزَحِيَّةِ والجِسْمِ الهَدَبِيّ).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورُّم القرنية، وهي الطبقة الشفافة لمقلة العين (وذمة بالقرنية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف في العين (نزيف في الجسم الزجاجي للعين).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الرؤية المفاجئ بسبب انسداد الأوعية الدموية في الجزء الخلفي من العين (انسداد الأوعية الدموية في الشبكية)</p><p dir="RTL">&bull; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;التهاب الأوعية الدموية في الجزء الخلفي من العين (التهاب الأوعية الدموية في الشبكية)</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إذا ظهرت لديك أية آثار جانبية، فتحدَّث إلى طبيبك.يشمل ذلك أية آثار جانبية مُحتمَلة، غير المُدرجة في هذه النَّشرة. يمكنك أيضًا الإبلاغ عن الآثار الجانبية بشكل مباشر</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong><u>السرنجة:</u></strong></p><ul><li dir="RTL">يُحفظ هذا الدَّواء بعيدًا عن رؤية ومُتناوَل الأطفال.</li><li dir="RTL">لا تستخدم هذا الدَّواء بعد تاريخ انتهاء الصلاحية المدون على العبوة الكرتونية وعلى الملصق بعد كلمة &quot;EXP&quot;. يُشير تاريخ انتهاء الصَّلاحية إلى اليوم الأخير من ذلك الشهر.</li><li dir="RTL">يحفظ في الثلاجة (عند 2-8 درجة مئوية).</li><li dir="RTL">لا تعرضه للتَّجميد.</li><li dir="RTL">احتفظ بالسرنجة المُعبأة مُسبقًا في الشريط المغلق وفي العبوة الكرتونية الخارجية للحماية من الضوء.</li><li dir="RTL">قبل الاستخدام، يمكن الاحتفاظ بالشريط غير المفتوح مع السرنجة المُعبأة مُسبقًا في درجة حرارة الغرفة (لا تتعدى 30 درجة مئوية) لمدة تصل إلى 24 ساعة.</li></ul><p dir="RTL"><strong><u>&nbsp;</u></strong></p><p dir="RTL"><strong><u>القنينة:</u></strong></p><ul><li dir="RTL">يحفظ هذا الدَّواء بعيدًا عن رؤية ومُتناوَل الأطفال.</li><li dir="RTL">لا تستخدم هذا الدَّواء بعد تاريخ انتهاء الصلاحية المدون على العبوة الكرتونية وعلى الملصق بعد كلمة &quot;EXP&quot;. يُشير تاريخ انتهاء الصَّلاحية إلى اليوم الأخير من ذلك الشهر.</li><li dir="RTL">يحفظ في الثلاجة (عند 2-8 درجة مئوية).</li><li dir="RTL">لا تعرضه للتَّجميد.</li><li dir="RTL">احتفظ بالأمبولة في العبوة الكرتونية الخارجية للحماية من الضوء.</li><li dir="RTL">قبل الاستخدام، يمكن الاحتفاظ بالقنينة في درجة حرارة الغرفة (لا تتعدى 30 درجة مئوية) لمدة تصل إلى 24 ساعة.</li></ul><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong><u>السرنجة:</u></strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي برولوسيزوماب. يحتوي المللي لتر الواحد من المحلول المُعَد للحَقْن على 120 مجم برولوسيزوماب. تحتوي كل سرنجة مُعبأة مُسبقًا على 19.8 مجم برولوسيزوماب في 0.165 مللي لتر من المحلول. وهذا يوفر كمية صالحة للاستخدام لإعطاء جرعة واحدة قدرها 0.05 مللي لتر من المحلول الذي يحتوي على 6 مجم من برولوسيزوماب.</p><p dir="RTL"><em>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>المكونات الأخرى هي: سترات الصوديوم، سكروز، بوليسوربات 80، ماء للحَقْن.</p><p dir="RTL"><strong><u>القنينة:</u></strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي برولوسيزوماب. يحتوي المللي لتر الواحد من المحلول المُعَد للحَقْن على 120 مجم برولوسيزوماب. تحتوي كل قنينة على 27.6 مجم برولوسيزوماب في 0.23 مللي لتر من المحلول. وهذا يوفر كمية صالحة للاستخدام لإعطاء جرعة واحدة قدرها 0.05 مللي لتر من المحلول الذي يحتوي على 6 مجم من برولوسيزوماب.</p><p dir="RTL"><em>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>المكونات الأخرى هي: سترات الصوديوم، سكروز، بوليسوربات 80، ماء للحَقْن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">عقار بيوفيو 120 مجم/ مللي لتر محلول للحقن في سرنجة مُعبأة مُسبَقًا. هذا المنتج الدوائي هو عبارة عن محلول للحقن مُعقم، مُعد للاستخدام مرة واحدة، خالٍ من المواد الحافظة، عديم اللون مائل قليلًا للأصفر البني.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><ul><li dir="RTL">حجم العبوة هو سرنجة واحدة مُعبأة مُسبَقًا للاستخدام مرة واحدة فقط.</li><li dir="RTL">حجم العبوة هي قنينة واحدة وإبرة مرشح فظة (مقياس 18 x 1.2 مم &times; 40 مم ، 5 ميكرون) للاستخدام الفردي فقط.</li></ul><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>مالك حق التسويق لهذا المنتج هي شركة نوفارتس يوروفارم المحدودة، دوبلن، إيرلندا.</p><p dir="RTL">www.Novartis.com</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشركة المصنعة :</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السرنجة: مصنعة من قبل شركة الكون كوفيرير، بوورس، بلجيكيا</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القنينة: مصنعة من قبل شركة نوفارتس فارما أي جي، ستاين، سويسرا</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تم اعتماد هذه النَّشرة من قبل منظمة الأدوية الأوروبية  11\2021
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Beovu 120 mg/ml solution for injection in pre-filled syringe Beovu 120 mg/ml solution for injection
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One ml solution for injection contains 120 mg of brolucizumab*.

* Brolucizumab is a humanised monoclonal single-chain Fv (scFv) antibody fragment produced in
Escherichia coli cells by recombinant DNA technology. Beovu 120 mg/ml solution for injection in pre-filled syringe
Each pre-filled syringe contains 19.8 mg brolucizumab in 0.165 ml solution. This provides a usable amount to deliver a single dose of 0.05 ml solution containing 6 mg of brolucizumab.

Beovu 120 mg/ml solution for injection

Each vial contains 27.6 mg brolucizumab in 0.23 ml solution. This provides a usable amount to deliver a single dose of 0.05 ml solution containing 6 mg of brolucizumab.

For the full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection (injection).

Clear to slightly opalescent, colourless to slightly brownish-yellow aqueous solution.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Beovu is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (AMD).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Beovu must be administered by a qualified ophthalmologist experienced in intravitreal injections. <u>Posology</u></p><p>The recommended dose is 6 mg brolucizumab (0.05 ml solution) administered by intravitreal injection every 4 weeks (monthly) for the first 3 doses. Thereafter, the physician may individualise treatment intervals based on disease activity as assessed by visual acuity and/or anatomical parameters. A disease activity assessment is suggested 16 weeks (4 months) after treatment start. In patients without disease activity, treatment every 12 weeks (3 months) should be considered (see sections&nbsp;4.4 and 5.1).</p><p>&nbsp;</p><p>If visual and anatomical outcomes indicate that the patient is not benefiting from continued treatment, Beovu should be discontinued.</p><p>&nbsp;</p><p><em><u>Special populations </u>Elderly</em></p><p>No dosage adjustment is required in patients aged 65 years or above (see section 5.2).</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>No dosage adjustment is required in patients with renal impairment (see section 5.2).</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>Brolucizumab has not been studied in patients with hepatic impairment. No dosage adjustment is required in patients with hepatic impairment (see section 5.2).</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The safety and efficacy of brolucizumab in children and adolescents below 18 years of age have not been established. No data are available.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>Beovu is for intravitreal use only.</p><p>&nbsp;</p><p>The solution for injection should be inspected visually prior to administration (see section 6.6).</p><p>&nbsp;</p><p>The intravitreal injection procedure should be carried out under aseptic conditions, which includes the use of surgical hand disinfection, sterile gloves, a sterile drape and a sterile eyelid speculum (or equivalent). Sterile paracentesis equipment should be available as a precautionary measure. The patient&rsquo;s medical history for hypersensitivity reactions should be carefully evaluated prior to performing the intravitreal procedure (see section 4.3). Adequate anaesthesia and a broad-spectrum topical microbicide to disinfect the periocular skin, eyelid and ocular surface should be administered prior to the injection.</p><p>&nbsp;</p><p>The injection needle should be inserted 3.5 to 4.0 mm posterior to the limbus into the vitreous cavity, avoiding the horizontal meridian and aiming towards the centre of the globe. The injection volume of</p><p>0.05 ml is then delivered slowly; a different scleral site should be used for subsequent injections.</p><p>&nbsp;</p><p>Immediately following the intravitreal injection, patients should be monitored for elevation in intraocular pressure. Appropriate monitoring may consist of a check for perfusion of the optic nerve head or tonometry. If required, sterile equipment for paracentesis should be available.</p><p>&nbsp;</p><p>Following intravitreal injection patients should be instructed to report any symptoms suggestive of endophthalmitis (e.g. eye pain, redness of the eye, photophobia, blurring of vision) without delay.</p><p>&nbsp;</p><p><em><u>Pre-filled syringe</u></em></p><p>The pre-filled syringe is for single use only. Each pre-filled syringe should only be used for the treatment of a single eye.</p><p>&nbsp;</p><p>Since the volume contained in the pre-filled syringe (0.165 ml) is greater than the recommended dose (0.05 ml), a portion of the volume contained in the pre-filled syringe must be discarded prior to administration.</p><p>&nbsp;</p><p>Injecting the entire volume of the pre-filled syringe could result in overdose. To expel the air bubble along with excess medicinal product, the plunger should be slowly depressed until the edge below the dome of the rubber stopper is aligned with the 0.05 ml dose mark (equivalent to 50 &micro;l, i.e. 6 mg brolucizumab).</p><p>&nbsp;</p><p><em><u>Vial</u></em></p><p>The vial is for single use only. Each vial should only be used for the treatment of a single eye.</p><p>&nbsp;</p><p>Since the volume contained in the vial (0.23 ml) is greater than the recommended dose (0.05 ml), a portion of the volume contained in the vial must be discarded prior to administration.</p><p>&nbsp;</p><p>Injecting the entire volume of the vial could result in overdose. To expel the air bubble along with excess medicinal product, the air should be carefully expelled from the syringe and the dose adjusted to the 0.05 ml mark (equivalent to 50 &micro;l, i.e. 6 mg brolucizumab).</p><p>&nbsp;</p><p>For instructions on preparation of the medicinal product before administration, see section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Patients with active or suspected ocular or periocular infections.
Patients with active intraocular inflammation.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Traceability</u></p><p>&nbsp;</p><p>In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</p><p>&nbsp;</p><p><u>&nbsp;Endophthalmitis, intraocular inflammation, traumatic cataract, retinal detachment, retinal vasculitis, and/or retinal vascular occlusion</u></p><p>Intravitreal injections, including those with Beovu, have been associated with endophthalmitis, intraocular inflammation, traumatic cataract and retinal detachment (see section 4.8). Proper aseptic injection techniques must always be used when administering Beovu.</p><p>&nbsp;</p><p>Patients should be instructed to report any symptoms suggestive of the above‑mentioned events without delay.</p><p>&nbsp;</p><p><u>Intraocular inflammation, including retinal vasculitis and/or retinal vascular occlusion</u></p><p>&nbsp;</p><p>Intraocular inflammation, including retinal vasculitis and/or retinal vascular occlusion, has been reported with the use of Beovu (see sections&nbsp;4.3 and 4.8). A higher number of intraocular inflammation events were observed among patients with treatment-emergent antibodies. After investigation, retinal vasculitis and/or retinal vascular occlusion were found to be immune‑mediated events. Intraocular inflammation, including retinal vasculitis and/or retinal vascular occlusion, may occur following the first intravitreal injection and at any time of treatment. These events were observed more frequently at the beginning of the treatment.</p><p>&nbsp;</p><p>Based on clinical studies these events were more frequent in female patients treated with Beovu than male patients (e.g.&nbsp;5.3% females vs.&nbsp;3.2% males in HAWK and HARRIER) and in Japanese patients.</p><p>&nbsp;</p><p>In patients developing these events, treatment with Beovu should be discontinued and the events should be promptly managed. Patients treated with Beovu with a medical history of intraocular inflammation and/or retinal vascular occlusion (within 12&nbsp;months prior to the first brolucizumab injection) should be closely monitored, since they are at increased risk of developing retinal vasculitis and/or retinal vascular occlusion.</p><p>&nbsp;</p><p>The interval between two Beovu doses during maintenance treatment should not be less than 8&nbsp;weeks considering that a higher incidence of intraocular inflammation (including retinal vasculitis) and retinal vascular occlusion was reported in patients with nAMD who received Beovu every 4&nbsp;week maintenance dosing in a clinical study compared to patients who received Beovu every 8 or 12&nbsp;week maintenance dosing in the pivotal Phase&nbsp;III clinical studies.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Intraocular pressure increases</u></p><p>&nbsp;</p><p>Transient increases in intraocular pressure have been seen within 30 minutes of intravitreal injection with vascular endothelial growth factor (VEGF) inhibitors, including brolucizumab (see section 4.8). Special precaution is needed in patients with poorly controlled glaucoma (do not inject Beovu while the intraocular pressure is &ge;30 mmHg). Both intraocular pressure and perfusion of the optic nerve head must be monitored and managed appropriately.</p><p>&nbsp;</p><p><u>Bilateral treatment</u></p><p>&nbsp;</p><p>The safety and efficacy of brolucizumab administered in both eyes concurrently have not been studied.</p><p>&nbsp;</p><p><u>Immunogenicity</u></p><p>&nbsp;</p><p>As this is a therapeutic protein, there is a potential for immunogenicity with brolucizumab (see section 4.8). Patients should be instructed to inform their physician if they develop symptoms such as eye pain or increased discomfort, worsening eye redness, blurred or decreased vision, an increased number of small particles in their vision, or increased sensitivity to light (see section 4.8).</p><p>&nbsp;</p><p><u>Concomitant use of other anti-VEGF</u></p><p>&nbsp;</p><p>There are no data available on the concomitant use of Beovu with other anti-VEGF medicinal products in the same eye. Brolucizumab should not be administered concurrently with other anti-VEGF medicinal products (systemic or ocular).</p><p>&nbsp;</p><p><u>Withholding treatment</u></p><p>&nbsp;</p><p>In intravitreal anti-VEGF treatments, the dose should be withheld and treatment should not be resumed earlier than the next scheduled treatment in the event of:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a decrease in best-corrected visual acuity (BCVA) of &ge;30 letters compared with the last assessment of visual acuity;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a retinal break;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a subretinal haemorrhage involving the centre of the fovea, or, if the size of the haemorrhage is</p><p>&ge;50% of the total lesion area;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; performed or planned intraocular surgery within the previous or next 28 days.</p><p>&nbsp;</p><p><u>Retinal pigment epithelial tear</u></p><p>&nbsp;</p><p>Risk factors associated with the development of a retinal pigment epithelial tear after anti-VEGF therapy for wet AMD include a large and/or high pigment epithelial retinal detachment. When initiating brolucizumab therapy, caution should be used in patients with these risk factors for retinal pigment epithelial tears.</p><p>&nbsp;</p><p><u>Rhegmatogenous retinal detachment or macular holes</u></p><p>&nbsp;</p><p>Treatment should be discontinued in subjects with rhegmatogenous retinal detachment or stage 3 or 4 macular holes.</p><p>&nbsp;</p><p><u>Systemic effects following intravitreal use</u></p><p>&nbsp;</p><p>Systemic adverse events, including non-ocular haemorrhages and arterial thromboembolic events, have been reported following intravitreal injection of VEGF inhibitors and there is a theoretical risk that these may relate to VEGF inhibition. There are limited data on safety in the treatment of patients with AMD with a history of stroke, transient ischaemic attacks or myocardial infarction within the last 3 months. Caution should be exercised when treating such patients.</p><p>&nbsp;</p><p><u>Sodium content</u></p><p>&nbsp;</p><p>This medicinal product contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially &ldquo;sodium-free&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No interaction studies have been performed.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential</u></p><p>&nbsp;</p><p>Women of childbearing potential should use effective contraception during treatment with brolucizumab and for at least one month after the last dose when stopping treatment with brolucizumab.</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>&nbsp;</p><p>There are no or limited amount of data from the use of brolucizumab in pregnant women. Animal studies are insufficient with respect to reproductive toxicity (see section 5.3). Although the systemic exposure after ocular administration is very low, brolucizumab should not be used during pregnancy unless the potential benefit outweighs the potential risk to the foetus.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p>It is unknown whether brolucizumab is excreted in human milk. A risk to the breast-fed newborn/infant cannot be excluded. Brolucizumab is not recommended during breast-feeding and breast-feeding should not be started for at least one month after the last dose when stopping treatment with brolucizumab. A decision must be made whether to discontinue breast-feeding or to abstain from brolucizumab therapy, taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>No reproductive or fertility studies have been conducted. VEGF inhibition has been shown to affect follicular development, corpus luteum function and fertility. Based on the mechanism of action of VEGF inhibitiors, there is a potential risk for female reproduction, and to embryofoetal development.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Beovu has a minor influence on the ability to drive and use machines due to possible temporary visual disturbances following the intravitreal injection and the associated eye examination. Patients should not drive or use machines until visual function has recovered sufficiently.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>&nbsp;</p><p>The most frequently reported adverse reactions were reduced visual acuity (7.3%), cataract (7.0%), conjunctival haemorrhage (6.3%) and vitreous floaters (5.1%).</p><p>&nbsp;</p><p>The most serious adverse reactions were blindness (0.8%), endophthalmitis (0.7%), retinal artery occlusion (0.8%) and retinal detachment (0.7%).</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p>Adverse reactions (Table 1) are listed according to the MedDRA system organ class. Within each system organ class, the adverse reactions are ranked by frequency, with the most frequent reactions first. Frequency categories for each adverse reaction are based on the following convention: very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to</p><p>&lt;1/1,000), very rare (&lt;1/10,000), not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p>Table 1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Frequencies of adverse reactions in clinical studies and post marketing experiance</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>MedDRA System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency category</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Hypersensitivity (including urticaria, rash, pruritus, erythema)</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Eye disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Visual acuity reduced</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Retinal haemorrhage</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Uveitis</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Iritis</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Vitreous detachment</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Retinal tear</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Cataract</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Conjunctival haemorrhage</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Vitreous floaters</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Eye pain</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Intraocular pressure increase</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Conjunctivitis</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Retinal pigment epithelial tear</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Vision blurred</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Corneal abrasion</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Punctate keratitis</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Blindness</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Endophthalmitis</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Retinal detachment</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Conjunctival hyperaemia</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Lacrimation increased</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Abnormal sensation in eye</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Detachment of retinal pigment epithelium</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Vitritis</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Anterior chamber inflammation</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Iridocyclitis</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Anterior chamber flare</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Corneal oedema</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Vitreous haemorrhage</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Retinal vascular occlusion</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Retinal vasculitis</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><u>Description of selected adverse reactions</u></p><p>&nbsp;</p><p><em><u>Immunogenicity</u></em></p><p>There is a potential for an immune response in patients treated with Beovu. After dosing with Beovu for 88 weeks, treatment-emergent anti-brolucizumab antibodies were detected in 23&ndash;25% of patients. Among patients with treatment-emergent antibodies, a higher number of intraocular inflammation adverse reactions were observed. After investigation, retinal vasculitis and/or retinal vascular occlusion, typically in the presence of intraocular inflammation, were found to be immune‑mediated adverse events related to exposure to Beovu (see section&nbsp;4.4). Anti-brolucizumab antibodies were not associated with an impact on clinical efficacy.</p><p>&nbsp;</p><p><em><u>Product-class-related adverse reactions</u></em></p><p>There is a theoretical risk of arterial thromboembolic events, including stroke and myocardial infarction, following intravitreal use of VEGF inhibitors. A low incidence rate of arterial thromboembolic events was observed in the brolucizumab clinical studies in patients with AMD. There were no major notable differences between the groups treated with brolucizumab and comparator.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions.</p><p>&nbsp;</p><p>To report any side effect(s):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Arabia</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Food and Drug Authority National Pharmacovigilance Center (NPC):</p><p>&nbsp;</p><p>o Fax: +966112057662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2340.</p><p>o Toll free phone: 8002490000</p><p>o SFDA call center: 19999</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patient Safety Department Novartis Consulting AG - Saudi Arabia:</p><p>&nbsp;</p><p>o Toll Free Number: 8001240078</p><p>o Phone: +966112658100</p><p>o Fax: +966112658107</p><p>o Email: adverse.events@novartis.com</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp; Other GCC States:</p><p>-&nbsp; Please contact the relevant competent authority.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Overdosing with greater than recommended injection volume may increase intraocular pressure. In the event of overdose, intraocular pressure should therefore be monitored and, if deemed necessary by the treating physician, appropriate treatment should be initiated.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Ophthalmologicals, antineovascularisation agents, ATC code: S01LA06 <u>Mechanism of action</u></p><p>Brolucizumab is a humanised monoclonal single chain Fv (scFv) antibody fragment with a molecular weight of ~26 kDa.</p><p>&nbsp;</p><p>Increased levels of signalling through the vascular endothelial growth factor A (VEGF-A) pathway are associated with pathological ocular angiogenesis and retinal oedema. Brolucizumab binds with high affinity to VEGF-A isoforms (e.g. VEGF110, VEGF121, and VEGF165), thereby preventing binding of VEGF-A to its receptors VEGFR-1 and VEGFR-2. By inhibiting VEGF-A binding, brolucizumab suppresses endothelial cell proliferation, thereby reducing pathological neovascularisation and decreasing vascular permeability.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>&nbsp;</p><p>Neovascular (wet) age-related macular degeneration (AMD) is characterised by pathological choroidal neovascularisation (CNV). Leakage of blood and fluid from CNV may cause retinal thickening or oedema and/or intraretinal/subretinal haemorrhage, resulting in loss of visual acuity.</p><p>&nbsp;</p><p>In the HAWK and HARRIER studies, related anatomical parameters were part of the disease activity assessments guiding treatment decisions. Reductions in central subfield thickness (CST) and in presence of intraretinal/subretinal fluid (IRF/SRF) or sub-retinal pigment epithelium (sub-RPE) fluid were observed in patients treated with Beovu as early as 4 weeks after treatment initiation and up to week 48 and week 96.</p><p>&nbsp;</p><p>At week 16, the reduction in CST was statistically significant on Beovu versus aflibercept in both studies (HAWK: -161 vs. -134 microns; HARRIER: -174 vs. -134 microns). This decrease from baseline in CST was also statistically significant at week 48 (HAWK: -173 vs. -144 microns; HARRIER: -194 vs. -144 microns), and maintained to the end of each study at week 96 (HAWK: -175 vs. -149 microns; HARRIER: -198 vs. -155 microns).</p><p>&nbsp;</p><p>At week 16, the percentage difference in patients with IRF and/or SRF fluid was statistically significant on Beovu versus aflibercept in both studies (HAWK: 34% vs. 52%; HARRIER: 29% vs. 45%). This difference was also statistically significant at week 48 (HAWK: 31% vs. 45%; HARRIER: 26% vs. 44%), and maintained to the end of each study at week 96 (HAWK: 24% vs. 37%; HARRIER: 24% vs. 39%).</p><p>&nbsp;</p><p>At week 16, the percentage difference in patients with sub-RPE fluid was statistically significant on Beovu versus aflibercept in both studies (HAWK: 19% vs. 27%; HARRIER: 16% vs. 24%). This difference was also statistically significant at week 48 (HAWK: 14% vs. 22%; HARRIER: 13% vs. 22%), and maintained to the end of each study at week 96 (HAWK: 11% vs. 15%; HARRIER: 17% vs. 22%).</p><p>&nbsp;</p><p>In these studies, for patients treated with Beovu, reductions in CNV lesion size were observed as early as 12 weeks, and at weeks 48 and 96 after treatment initiation.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p>The efficacy and safety of Beovu were assessed in two randomised, multicentre, double-masked, active-controlled Phase III studies (HAWK and HARRIER) in patients with neovascular (wet) AMD. A total of 1,817 patients were treated in these studies for two years (1,088 on Beovu and 729 on comparator aflibercept). Patient ages ranged from 50 to 97 years, with a mean age of 76 years.</p><p>&nbsp;</p><p>In both studies, after the first three monthly doses (weeks 0, 4 and 8), brolucizumab patients were treated every 12 weeks, with the option of adjusting to a dosing interval every 8 weeks based on disease activity. Disease activity was assessed by a physician during the first 12-week interval (at weeks 16 and 20) and at each subsequent scheduled 12-weekly treatment visit. Patients who showed disease activity (e.g. decreased visual acuity, increased CST and/or presence of IRF/SRF or sub-RPE fluid) at any of these visits were adjusted to an 8-weekly treatment interval. The comparator aflibercept was administered every 8 weeks after the first 3 monthly doses.</p><p>&nbsp;</p><p><em><u>Results</u></em></p><p>The primary efficacy endpoint for the studies was the change from baseline in best corrected visual acuity (BCVA) to week 48, as measured by the early treatment diabetic retinopathy study (ETDRS) letter score, with the primary objective being to demonstrate non-inferiority of Beovu versus aflibercept. In both studies, Beovu (administered in an every 12 weeks or an every 8 weeks regimen) demonstrated non-inferior efficacy to aflibercept 2 mg (administered every 8 weeks). The visual acuity gains observed in the first year were maintained in the second year.</p><p>&nbsp;</p><p>Detailed results of both studies are shown in Table 2 and in Figure 1 below.</p><p>&nbsp;</p><p>Table 2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Visual acuity outcomes at weeks 48 and 96 in Phase III - HAWK and HARRIER studies</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p><strong>HAWK</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>HARRIER</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Efficacy outcome</strong></p></td><td style="vertical-align:top"><p><strong>Week</strong></p></td><td style="vertical-align:top"><p><strong>Beovu 6 mg (n=360)</strong></p></td><td style="vertical-align:top"><p><strong>Aflibercept 2 mg (n=360)</strong></p></td><td style="vertical-align:top"><p><strong>Difference (95% CI)</strong></p><p><strong>brolucizumab</strong></p><p><strong>&ndash; aflibercept</strong></p></td><td style="vertical-align:top"><p><strong>Beovu 6 mg (n=370)</strong></p></td><td style="vertical-align:top"><p><strong>Aflibercept 2 mg (n=369)</strong></p></td><td style="vertical-align:top"><p><strong>Difference (95% CI)</strong></p><p><strong>brolucizumab</strong></p><p><strong>&ndash; aflibercept</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Mean change from</strong></p></td><td style="vertical-align:top"><p>48</p></td><td style="vertical-align:top"><p>6.6</p></td><td style="vertical-align:top"><p>6.8</p></td><td style="vertical-align:top"><p>-0.2</p></td><td style="vertical-align:top"><p>6.9</p></td><td style="vertical-align:top"><p>7.6</p></td><td style="vertical-align:top"><p>-0.7</p></td></tr><tr><td style="vertical-align:top"><p><strong>baseline in BCVA (measured by</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(SE=0.71)</p></td><td style="vertical-align:top"><p>(SE=0.71)</p></td><td style="vertical-align:top"><p>(-2.1, 1.8) P&lt;0.0001 a)</p></td><td style="vertical-align:top"><p>(SE=0.61)</p></td><td style="vertical-align:top"><p>(SE=0.61)</p></td><td style="vertical-align:top"><p>(-2.4, 1.0)</p><p>P &lt;0.0001 a)</p></td></tr><tr><td style="vertical-align:top"><p><strong>ETDRS letters score)</strong></p></td><td style="vertical-align:top"><p>36 &ndash;</p></td><td style="vertical-align:top"><p>6.7</p></td><td style="vertical-align:top"><p>6.7</p></td><td style="vertical-align:top"><p>0.0</p></td><td style="vertical-align:top"><p>6.5</p></td><td style="vertical-align:top"><p>7.7</p></td><td style="vertical-align:top"><p>-1.2</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>48 b)</p></td><td style="vertical-align:top"><p>(SE=0.68)</p></td><td style="vertical-align:top"><p>(SE=0.68)</p></td><td style="vertical-align:top"><p>(-1.9, 1.9)</p></td><td style="vertical-align:top"><p>(SE=0.58)</p></td><td style="vertical-align:top"><p>(SE=0.58)</p></td><td style="vertical-align:top"><p>(-2.8, 0.4)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>P&lt;0.0001 a)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>P=0.0003 a)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>96</p></td><td style="vertical-align:top"><p>5.9</p></td><td style="vertical-align:top"><p>5.3</p></td><td style="vertical-align:top"><p>0.5</p></td><td style="vertical-align:top"><p>6.1</p></td><td style="vertical-align:top"><p>6.6</p></td><td style="vertical-align:top"><p>-0.4</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(SE=0.78)</p></td><td style="vertical-align:top"><p>(SE=0.78)</p></td><td style="vertical-align:top"><p>(-1.6, 2.7)</p></td><td style="vertical-align:top"><p>(SE=0.73)</p></td><td style="vertical-align:top"><p>(SE=0.73)</p></td><td style="vertical-align:top"><p>(-2.5,1.6)</p></td></tr><tr><td style="vertical-align:top"><p><strong>% of patients who</strong></p></td><td style="vertical-align:top"><p>48</p></td><td style="vertical-align:top"><p>33.6</p></td><td style="vertical-align:top"><p>25.4</p></td><td style="vertical-align:top"><p>8.2</p></td><td style="vertical-align:top"><p>29.3</p></td><td style="vertical-align:top"><p>29.9</p></td><td style="vertical-align:top"><p>-0.6</p></td></tr><tr><td style="vertical-align:top"><p><strong>gained at least</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(2.2, 15.0)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(-7.1, 5.8)</p></td></tr><tr><td style="vertical-align:top"><p><strong>15 letters of vision</strong></p></td><td style="vertical-align:top"><p>96</p></td><td style="vertical-align:top"><p>34.2</p></td><td style="vertical-align:top"><p>27.0</p></td><td style="vertical-align:top"><p>7.2</p></td><td style="vertical-align:top"><p>29.1</p></td><td style="vertical-align:top"><p>31.5</p></td><td style="vertical-align:top"><p>-2.4</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(1.4, 13.8)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(-8.8, 4.1)</p></td></tr><tr><td style="vertical-align:top"><p><strong>% of patients who</strong></p></td><td style="vertical-align:top"><p>48</p></td><td style="vertical-align:top"><p>6.4</p></td><td style="vertical-align:top"><p>5.5</p></td><td style="vertical-align:top"><p>0.9</p></td><td style="vertical-align:top"><p>3.8</p></td><td style="vertical-align:top"><p>4.8</p></td><td style="vertical-align:top"><p>-1.0</p></td></tr><tr><td style="vertical-align:top"><p><strong>lost visual acuity (%)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(-2.7, 4.3)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(-3.9, 2.2)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>(&ge;15 letters of BCVA loss)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>96</p></td><td style="vertical-align:top"><p>8.1</p></td><td style="vertical-align:top"><p>7.4</p></td><td style="vertical-align:top"><p>0.7</p><p>(-3.6, 4.6)</p></td><td style="vertical-align:top"><p>7.1</p></td><td style="vertical-align:top"><p>7.5</p></td><td style="vertical-align:top"><p>-0.4</p><p>(-3.8, 3.3)</p></td></tr><tr><td colspan="8" style="vertical-align:top"><p>BCVA: best corrected visual acuity; missing data are imputed using last observation carried forward (LOCF) method ETDRS: early treatment diabetic retinopathy study</p><p>a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; P-value referring to the non-inferiority hypothesis with a non-interiority margin of 4.0 letters.</p><p>b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Key secondary endpoint, accounting for differences in timing of Beovu and aflibercept treatments.</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Figure 1&nbsp;&nbsp;&nbsp;&nbsp; Mean change in visual acuity from baseline to week 96 in HAWK and HARRIER studies</strong></p><p><strong>&nbsp;</strong></p><p><strong>HAWK</strong></p><p><strong>&nbsp;</strong></p><p><!--[if gte vml 1]><v:group id="Group_x0020_24"
 o:spid="_x0000_s1048" style='position:absolute;left:0;text-align:left;
 margin-left:130.55pt;margin-top:8.85pt;width:376.7pt;height:168.65pt;
 z-index:251659264;mso-position-horizontal-relative:page' coordorigin="2611,177"
 coordsize="7534,3373" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:line id="Line_x0020_3" o:spid="_x0000_s1049" style='position:absolute;
  visibility:visible;mso-wrap-style:square' from="2690,182" to="2690,3410"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight=".17692mm"/>
 <v:line id="Line_x0020_4" o:spid="_x0000_s1050" style='position:absolute;
  visibility:visible;mso-wrap-style:square' from="2750,3471" to="10065,3471"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" strokeweight=".26539mm"/>
 <v:shape id="Freeform_x0020_5" o:spid="_x0000_s1051" style='position:absolute;
  left:2690;top:1169;width:7375;height:2302;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' coordsize="7375,2302" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,2302l308,1019,615,428,922,263r307,-99l1536,198r308,-34l2151,32,2458,r307,99l3072,66r308,l3687,131r307,67l4301,229r307,-31l4916,229r309,34l5532,395r308,-99l6147,229r307,199l6761,361r307,-31l7375,361e"
  filled="f" strokeweight=".35386mm">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,3471;308,2188;615,1597;922,1432;1229,1333;1536,1367;1844,1333;2151,1201;2458,1169;2765,1268;3072,1235;3380,1235;3687,1300;3994,1367;4301,1398;4608,1367;4916,1398;5225,1432;5532,1564;5840,1465;6147,1398;6454,1597;6761,1530;7068,1499;7375,1530"
   o:connectangles="0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0"/>
 </v:shape><v:shape id="AutoShape_x0020_6" o:spid="_x0000_s1052" style='position:absolute;
  left:2611;top:1090;width:7534;height:2460;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' coordsize="7534,2460" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m158,2380l79,2301,,2380r79,80l158,2380m465,1096r-79,-79l307,1096r79,80l465,1096m773,506l693,427r-79,79l693,585r80,-79m1080,340r-79,-79l921,340r80,80l1080,340t307,-98l1308,163r-79,79l1308,321r79,-79m1694,276r-79,-80l1536,276r79,79l1694,276t307,-34l1922,163r-79,79l1922,321r79,-79m2309,110l2229,31r-79,79l2229,189r80,-79m2616,79l2537,r-80,79l2537,158r79,-79m2923,177l2844,98r-79,79l2844,256r79,-79m3230,144l3151,64r-79,80l3151,223r79,-79m3537,144l3458,64r-79,80l3458,223r79,-79m3845,208r-80,-79l3686,208r79,80l3845,208t307,68l4073,196r-80,80l4073,355r79,-79m4459,307r-79,-79l4301,307r79,79l4459,307t307,-31l4687,196r-79,80l4687,355r79,-79m5073,307r-79,-79l4915,307r79,79l5073,307t310,33l5304,261r-79,79l5304,420r79,-80m5690,472r-79,-79l5532,472r79,80l5690,472t307,-98l5918,295r-79,79l5918,453r79,-79m6305,307r-80,-79l6146,307r79,79l6305,307t307,199l6533,427r-80,79l6533,585r79,-79m6919,439r-79,-79l6761,439r79,79l6919,439t307,-31l7147,328r-79,80l7147,487r79,-79m7533,439r-79,-79l7375,439r79,79l7533,439e"
  fillcolor="black" stroked="f">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="79,3391;79,3550;465,2186;307,2186;465,2186;693,1517;693,1675;1080,1430;921,1430;1080,1430;1308,1253;1308,1411;1694,1366;1536,1366;1694,1366;1922,1253;1922,1411;2309,1200;2150,1200;2309,1200;2537,1090;2537,1248;2923,1267;2765,1267;2923,1267;3151,1154;3151,1313;3537,1234;3379,1234;3537,1234;3765,1219;3765,1378;4152,1366;3993,1366;4152,1366;4380,1318;4380,1476;4766,1366;4608,1366;4766,1366;4994,1318;4994,1476;5383,1430;5225,1430;5383,1430;5611,1483;5611,1642;5997,1464;5839,1464;5997,1464;6225,1318;6225,1476;6612,1596;6453,1596;6612,1596;6840,1450;6840,1608;7226,1498;7068,1498;7226,1498;7454,1450;7454,1608"
   o:connectangles="0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0"/>
 </v:shape><v:shape id="Freeform_x0020_7" o:spid="_x0000_s1053" style='position:absolute;
  left:2690;top:1202;width:7375;height:2269;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' coordsize="7375,2269" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,2269l308,954,615,328,922,263r307,34l1536,r308,66l2151,131r307,34l2765,r307,66l3380,131,3687,33r307,65l4301,r307,131l4916,165r309,31l5532,297r308,-34l6147,426r307,68l6761,426r307,-31l7375,525e"
  filled="f" strokecolor="#a4a4a4" strokeweight=".35386mm">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,3471;308,2156;615,1530;922,1465;1229,1499;1536,1202;1844,1268;2151,1333;2458,1367;2765,1202;3072,1268;3380,1333;3687,1235;3994,1300;4301,1202;4608,1333;4916,1367;5225,1398;5532,1499;5840,1465;6147,1628;6454,1696;6761,1628;7068,1597;7375,1727"
   o:connectangles="0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0"/>
 </v:shape><v:shape id="AutoShape_x0020_8" o:spid="_x0000_s1054" style='position:absolute;
  left:2630;top:1140;width:7496;height:2391;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' coordsize="7496,2391" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m120,2270l,2270r,120l120,2390r,-120m427,955r-120,l307,1075r120,l427,955m734,329r-120,l614,449r120,l734,329t308,-65l922,264r,120l1042,384r,-120m1349,298r-120,l1229,418r120,l1349,298m1656,l1536,r,120l1656,120,1656,t307,67l1843,67r,120l1963,187r,-120m2270,132r-120,l2150,252r120,l2270,132t308,34l2458,166r,120l2578,286r,-120m2885,l2765,r,120l2885,120,2885,t307,67l3072,67r,120l3192,187r,-120m3499,132r-120,l3379,252r120,l3499,132m3806,34r-120,l3686,154r120,l3806,34t308,64l3994,98r,120l4114,218r,-120m4421,l4301,r,120l4421,120,4421,t307,132l4608,132r,120l4728,252r,-120m5035,166r-120,l4915,286r120,l5035,166t310,31l5225,197r,120l5345,317r,-120m5652,298r-120,l5532,418r120,l5652,298t307,-34l5839,264r,120l5959,384r,-120m6266,427r-120,l6146,547r120,l6266,427t308,67l6454,494r,120l6574,614r,-120m6881,427r-120,l6761,547r120,l6881,427t307,-31l7068,396r,120l7188,516r,-120m7495,526r-120,l7375,646r120,l7495,526e"
  fillcolor="#a4a4a4" stroked="f">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,3410;120,3530;427,2095;307,2215;427,2095;614,1469;734,1589;1042,1404;922,1524;1042,1404;1229,1438;1349,1558;1656,1140;1536,1260;1656,1140;1843,1207;1963,1327;2270,1272;2150,1392;2270,1272;2458,1306;2578,1426;2885,1140;2765,1260;2885,1140;3072,1207;3192,1327;3499,1272;3379,1392;3499,1272;3686,1174;3806,1294;4114,1238;3994,1358;4114,1238;4301,1140;4421,1260;4728,1272;4608,1392;4728,1272;4915,1306;5035,1426;5345,1337;5225,1457;5345,1337;5532,1438;5652,1558;5959,1404;5839,1524;5959,1404;6146,1567;6266,1687;6574,1634;6454,1754;6574,1634;6761,1567;6881,1687;7188,1536;7068,1656;7188,1536;7375,1666;7495,1786"
   o:connectangles="0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0"/>
 </v:shape><v:shape id="AutoShape_x0020_9" o:spid="_x0000_s1055" style='position:absolute;
  left:6373;top:1348;width:3682;height:2143;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' coordsize="3682,2143" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m3681,430r,1713m,l,2131e" filled="f" strokecolor="#a4a4a4"
  strokeweight=".5pt">
  <v:stroke dashstyle="3 1"/>
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="3681,1778;3681,3491;0,1348;0,3479"
   o:connectangles="0,0,0,0"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="503" height="226" src="file:///C:/Users/alrasha1/AppData/Local/Temp/9/msohtmlclip1/01/clip_image001.png" />10</p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_23" o:spid="_x0000_s1047"
 type="#_x0000_t202" style='position:absolute;left:0;text-align:left;
 margin-left:87.65pt;margin-top:18.35pt;width:11pt;height:124.2pt;z-index:251664384;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
 mso-height-relative:page;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF
dyTewfKKEqcMCKEmHfgZgaE8wMW+SSwc27JvS/v23KTJgkoXFsu+P+c7Ol5vDoMTe0zZBl/LVVlJ
gV4HY31Xy4/tS3EvRSbwBlzwWMsjZrlprq/W22PELHjb51r2RPFBqax7HCCXIaLnThvSAMTP1KkI
+gs6VLdVdad08ISeCho1ZLN+whZ2jsTzgcsnJwldluLxNDiyagkxOquB2Knae/OLUsyEkjenmdzb
mG/YhlRnCWPnb8C898bRJGtQvEOiVxjYhtLOxs8AySiT4JuDystlVV4WPeM6tK3VaILeDZxIOSsu
ti/jidNGNZ3/J08yC1dNv9v8AAAA//8DAFBLAwQUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAF9y
ZWxzLy5yZWxzhI/NCsIwEITvgu8Q9m7TehCRpr2I4FX0AdZk2wbbJGTj39ubi6AgeJtl2G9m6vYx
jeJGka13CqqiBEFOe2Ndr+B03C3WIDihMzh6RwqexNA281l9oBFTfuLBBhaZ4ljBkFLYSMl6oAm5
8IFcdjofJ0z5jL0MqC/Yk1yW5UrGTwY0X0yxNwri3lQgjs+Qk/+zfddZTVuvrxO59CNCmoj3vCwj
MfaUFOjRhrPHaN4Wv0VV5OYgm1p+LW1eAAAA//8DAFBLAwQUAAYACAAAACEAn+OtEKkEAABjJgAA
HwAAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWzsWktv4zYQvhfofyB0ag+KJVvyC6ss
EjteFEi3QbzbO01RFlGKVEnGdlr0v3dIWbFst2mUTXqSA9h8jIYzH78ZMSQ/fNwVHG2o0kyKxAsv
Ag9RQWTKxDrxvn5Z+GMPaYNFirkUNPEeqfY+Xn7/3Qc8XStc5owg0CD0FCdebkw57fU0yWmB9YUs
qYC+TKoCG6iqdS9VeAuaC97rB8GwV2AmvMuDqjk2GD0o9gpVXJLfaDrDYoM1qORk2mzZ28jJt2vG
U7H5pMpleaes5eTz5k4hliYeICdwARB5vX3HXgyqvZOn1gcFu0wVVl5mGdrBDIThIIxjDz1CeRKP
B1FQ6aM7g4gVGExGAYxFrEA8Gj0JkPyX/1BB8pvnlYCZlTlQaJioS2ug2Jz73B/UTn+x9l3LHYKm
2n8rj8wOWsFUN8+6vIV50kjIWY7Fml4pJbc5xam2EhVQgGg1kAOtHlNbXavtzzIFhPGDkU7fG4H3
5DeelkqbT1QWyBYST1Fi3Eh4c6tNZWAt4kCRC8a5c5iLowbQWbUAMPCo7bMQOXb/OQkmN+ObceRH
/eGNHwXzuX+1mEX+cBGO4vlgPpvNw7/suGE0zVmaUmGHqSMtjM5oXDCipJaZuSCy6AGXGKF1tEGs
hcEh1rTkLLXqrElarVczrtAG88RbuM9+GhpivWMzHJ3BlxOXwn4UXPcn/mI4HvnRIop9IOrYD8LJ
9WQYRJNovjh26ZYJ+u0uoW3iTeJ+XPHrX30L3OfcNzwtmKEKcVYk3vhJCE8tK29E6qbWYMarcgMK
a/4BCpjueqKhaNlq4TG7pYsdGwTpo21ZwS8wWUkgF0QxZF4o2O/+CKpbSKmJp39/wIp6iP8kIC6g
2dQFVRdWdQELkkuVeMZDVXFmoAbPPJSKrXNQXkWekFcQNBnbc7gywxrEtVmaR06do85YG2kFVrfw
KBgFqqByb3U6cbEsiS3oktwZXREnDMJ4Dy1v9F/T7FTSJTMHEDn0XmWOS02NDTnXC4/sIXW4KjCR
QwJJPCr8r0t4Rf0BLABb7Xg0yyBqq3AF/7BhApnHkmaYQO6YYc5WinmoxEJqaAj6wSKI4dv+RcHA
fkMvMyRf4IJxyLMDaCA5Vpq6WXNQUdxQ+oUVVKPPdIvuZYHFkfJ+MASlMai2gwzOlIfwhj1VTvS7
KQckAT2Lk7n89cq+mQB822ibngcXwQwlnh92MJ8S5HwOmzCjVih3FD4OvuexJa2w3TO4ell0eeKQ
4Z4HOW8FckfgNgTGrbDtCPzit2gzA4t1K5Q7BrdhMG2FbcVgWC92ILcBud0aoksTr0oTmWpF5Y7B
bRgMeyqt0O04/CoOr1qB3FG4DYW7tdrTNsrb7ng012qaciY6Er/pjlIT39cs1wbdlk+35XO0JXq+
YQBnYf/PruUPrZJDt4x41TKCt0sT3TqizTrCdAyuj2Pebx1hOga/H7jt/lHe5+Du4OgFh3/NpZpu
lSe6HNwmB/94gi0V6R1W+P6fTpbD8EVHy28bbnCQ/X5HzMCyg8Pu/BeO/qHxcFHhQdNleQ8H6XDa
7TrsTQYo2MtAvZPrVa5jfx3M3uFq1i//BgAA//8DAFBLAwQUAAYACAAAACEAkS1qSVgGAAAPGgAA
GgAAAGNsaXBib2FyZC90aGVtZS90aGVtZTEueG1s7FlLbxs3EL4X6H9Y7L2x3oqNyIGtR9zEToJI
SZEjpaV2GXOXC5Kyo1uRnHopUCAtemiA3nooigZogAa99McYcNCmP6JD7kOkRMUPuEBQxAKM3dlv
hsOZ2W9I7o2bT2PqHWEuCEs6fvVaxfdwMmEBScKO/3A0+Oy67wmJkgBRluCOP8fCv7n96Sc30NaE
knTMEA9GEY6xB4YSsYU6fiRlurWxISYgRuIaS3ECz6aMx0jCLQ83Ao6OYYCYbtQqldZGjEjib4NF
qQz1KfxLpFCCCeVDZQZ7CYph9HvTKZlgjQ0Oqwoh5qJLuXeEaMcHmwE7HuGn0vcoEhIedPyK/vM3
tm9soK1cico1uobeQP/lerlCcFjTY/JwXA7aaDQbrZ3SvgZQuYrrt/utfqu0pwFoMoGZZr6YNpu7
m7u9Zo41QNmlw3av3atXLbxhv77i805T/Sy8BmX2Gyv4waALUbTwGpThmyv4RqNd6zYsvAZl+NYK
vl3Z6TXaFl6DIkqSwxV0pdmqd4vZlpApo3tO+GazMWjXcuMLFFRDWV1qiClL5Lpai9ETxgcAUECK
JEk8OU/xFE2gJruIkjEn3j4JIyi8FCVMgLhSqwwqdfivfg19pSOCtjAytJVf4IlYESl/PDHhJJUd
/zZY9Q3I6Zs3J89enzz7/eT585Nnv+Zja1OW3h5KQlPv3U/f/PPyS+/v33589+LbbOhlvDDxb3/5
6u0ff77PPMx4EYrT7169ff3q9Puv//r5hcP6DkdjEz4iMRbeXXzsPWAxTNDhPx7zi2mMIkRMjZ0k
FChBahSH/b6MLPTdOaLIgdvFdhwfcaAaF/DW7Inl8DDiM0kcFu9EsQU8YIzuMu6Mwh01lhHm0SwJ
3YPzmYl7gNCRa+wuSqws92cpcCxxmexG2HLzPkWJRCFOsPTUM3aIsWN2jwmx4npAJpwJNpXeY+Lt
IuIMyYiMrWpaKO2RGPIydzkI+bZic/DI22XUNesePrKR8G4g6nB+hKkVxltoJlHsMjlCMTUDvo9k
5HJyOOcTE9cXEjIdYsq8foCFcOnc4zBfI+l3gGbcaT+g89hGckkOXTb3EWMmsscOuxGKUxd2SJLI
xH4uDqFEkXefSRf8gNlviLqHPKBkbbofEWyl+2w2eAgMa7q0KBD1ZMYdubyFmVW/wzmdIqypBhqA
xesxSc4k+SV6b/539A4kevrDS8eMrobS3YatfFyQzHc4cb5Ne0sUvg63TNxdxgPy4fN2D82S+xhe
ldXm9ZG2P9K2/7+n7XXv89WT9YKfgbrVsjVbruvFe7x27T4llA7lnOJ9oZfvArpSMACh0tN7VFzu
5dIILtWbDANYuJAjreNxJr8gMhpGKIU1ftVXRkKRmw6FlzIBS38tdtpWeDqLD1iQbVmrVbU9zchD
ILmQV5qlHLYbMkO32ottWGleexvq7XLhgNK9iBPGYLYTdYcT7UKogqQ35xA0hxN6ZlfixabDi+vK
fJGqFS/AtTIrsGzyYLHV8ZsNUAEl2FUhigOVpyzVRXZ1Mq8y0+uCaVUArCGKClhkelP5unZ6anZZ
qZ0j05YTRrnZTujI6B4mIhTgvDqV9DxuXDTXm4uUWu6pUOjxoLQWbrSvv8+Ly+Ya9Ja5gSYmU9DE
O+74rXoTSmaC0o4/ha0/XMYp1I5Qy11EQzg0m0ievfCXYZaUC9lDIsoCrkknY4OYSMw9SuKOr6Zf
poEmmkO0b9UaEMIH69wm0MqH5hwk3U4ynk7xRJppNyQq0tktMHzGFc6nWv3yYKXJZpDuYRQce2M6
4w8QlFizXVUBDIiAE6BqFs2AwJFmSWSL+ltqTDntmmeKuoYyOaJphPKOYpJ5BtdUXrqj78oYGHf5
nCGgRkjyRjgOVYM1g2p107JrZD6s7bpnK6nIGaS56JkWq6iu6WYxa4SiDSzF8nJN3vCqCDFwmtnh
M+peptzNguuW1glll4CAl/FzdN1zNATDtcVglmvK41UaVpydS+3eUUzwDNfO0yQM1m8VZpfiVvYI
53AgvFTnB73lqgXRtFhX6ki7Pk8coNQbh9WOD58I4GziKVzBRwYfZDUlqykZXMGXA2gX2XF/x88v
Cgk8zyQlpl5I6gWmUUgahaRZSJqFpFVIWr6nz8XhW4w6Eve94tgbelh+TJ6vLexvONv/AgAA//8D
AFBLAwQUAAYACAAAACEAnGZGQbsAAAAkAQAAKgAAAGNsaXBib2FyZC9kcmF3aW5ncy9fcmVscy9k
cmF3aW5nMS54bWwucmVsc4SPzQrCMBCE74LvEPZu0noQkSa9iNCr1AcIyTYtNj8kUezbG+hFQfCy
MLPsN7NN+7IzeWJMk3ccaloBQae8npzhcOsvuyOQlKXTcvYOOSyYoBXbTXPFWeZylMYpJFIoLnEY
cw4nxpIa0cpEfUBXNoOPVuYio2FBqrs0yPZVdWDxkwHii0k6zSF2ugbSL6Ek/2f7YZgUnr16WHT5
RwTLpRcWoIwGMwdKV2edNS1dgYmGff0m3gAAAP//AwBQSwECLQAUAAYACAAAACEAu+VIlAUBAAAe
AgAAEwAAAAAAAAAAAAAAAAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQCt
MD/xwQAAADIBAAALAAAAAAAAAAAAAAAAADYBAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQCf
460QqQQAAGMmAAAfAAAAAAAAAAAAAAAAACACAABjbGlwYm9hcmQvZHJhd2luZ3MvZHJhd2luZzEu
eG1sUEsBAi0AFAAGAAgAAAAhAJEtaklYBgAADxoAABoAAAAAAAAAAAAAAAAABgcAAGNsaXBib2Fy
ZC90aGVtZS90aGVtZTEueG1sUEsBAi0AFAAGAAgAAAAhAJxmRkG7AAAAJAEAACoAAAAAAAAAAAAA
AAAAlg0AAGNsaXBib2FyZC9kcmF3aW5ncy9fcmVscy9kcmF3aW5nMS54bWwucmVsc1BLBQYAAAAA
BQAFAGcBAACZDgAAAAA=
" filled="f" stroked="f">
 <v:textbox style='layout-flow:vertical;mso-layout-flow-alt:bottom-to-top'
  inset="0,0,0,0">
  <![if RotText]><![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal style='margin-top:0in;margin-right:-21.1pt;margin-bottom:
    0in;margin-left:1.0pt;margin-bottom:.0001pt;line-height:10.15pt;mso-line-height-rule:
    exactly'><span style='font-size:9.0pt;mso-bidi-font-size:11.0pt;font-family:
    "Calibri",sans-serif;mso-hansi-font-family:"Times New Roman";mso-bidi-font-family:
    "Times New Roman"'>VA<span style='letter-spacing:-.1pt'> </span>c<span
    style='letter-spacing:-.05pt'>h</span>a<span style='letter-spacing:-.05pt'>ng</span>e<span
    style='letter-spacing:.15pt'> </span><span style='letter-spacing:-.05pt'>fr</span>om
    <span style='letter-spacing:-.05pt'>b</span>a<span style='letter-spacing:
    -.05pt'>selin</span>e<span style='letter-spacing:.3pt'> </span>(<span
    style='letter-spacing:-.05pt'>le</span>t<span style='letter-spacing:-.05pt'>te</span>r<span
    style='letter-spacing:-.1pt'>s</span>)<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]><![endif]></v:textbox>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="19" height="169" alt="Text Box: VA change from baseline (letters)" src="file:///C:/Users/alrasha1/AppData/Local/Temp/9/msohtmlclip1/01/clip_image002.png" />9</p><p>8</p><p>7</p><p>6</p><p>5</p><p>4</p><p>3</p><p>2</p><p>1</p><p>0</p><p>0&nbsp;&nbsp;&nbsp;&nbsp; 4&nbsp;&nbsp;&nbsp;&nbsp; 8&nbsp;&nbsp;&nbsp; 12&nbsp;&nbsp; 16&nbsp;&nbsp; 20&nbsp;&nbsp; 24&nbsp;&nbsp; 28&nbsp;&nbsp; 32&nbsp;&nbsp; 36&nbsp;&nbsp; 40&nbsp;&nbsp; 44&nbsp;&nbsp; 48&nbsp;&nbsp; 52&nbsp;&nbsp; 56&nbsp;&nbsp; 60&nbsp;&nbsp; 64&nbsp;&nbsp; 68&nbsp;&nbsp; 72&nbsp;&nbsp; 76&nbsp;&nbsp; 80&nbsp;&nbsp; 84&nbsp;&nbsp; 88&nbsp;&nbsp; 92&nbsp; &nbsp;96</p><p>&nbsp;</p><p>Time (weeks)</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:group id="Group_x0020_20"
 o:spid="_x0000_s1044" style='position:absolute;left:0;text-align:left;
 margin-left:205.8pt;margin-top:-8.05pt;width:20.25pt;height:5.05pt;z-index:251660288;
 mso-position-horizontal-relative:page' coordorigin="4116,-161" coordsize="405,101"
 o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:line id="Line_x0020_11" o:spid="_x0000_s1045" style='position:absolute;
  visibility:visible;mso-wrap-style:square' from="4127,-111" to="4511,-111"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQDWf8I3xAAAANsAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI/BasMw
EETvhf6D2EIupZFjsClulBAMheRQTJIeelysrWxqrYyl2M7fV4FAjsPMvGHW29l2YqTBt44VrJYJ
COLa6ZaNgu/z59s7CB+QNXaOScGVPGw3z09rLLSb+EjjKRgRIewLVNCE0BdS+rohi37peuLo/brB
YohyMFIPOEW47WSaJLm02HJcaLCnsqH673SxCvKv7HXsKgyHzPxcylLv8qo3Si1e5t0HiEBzeITv
7b1WkK7g9iX+ALn5BwAA//8DAFBLAQItABQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAAAAAAAAA
AAAAAAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsA
AAAAAAAAAAAAAAAAHwEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhANZ/wjfEAAAA2wAAAA8A
AAAAAAAAAAAAAAAABwIAAGRycy9kb3ducmV2LnhtbFBLBQYAAAAAAwADALcAAAD4AgAAAAA=
" strokeweight=".35386mm"/>
 <v:shape id="Freeform_x0020_12" o:spid="_x0000_s1046" style='position:absolute;
  left:4267;top:-161;width:101;height:101;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="101,101" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m51,l,50r51,50l101,50,51,xe" fillcolor="black" stroked="f">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="51,-161;0,-111;51,-61;101,-111;51,-161"
   o:connectangles="0,0,0,0,0"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="28" height="8" src="file:///C:/Users/alrasha1/AppData/Local/Temp/9/msohtmlclip1/01/clip_image003.png" /><!--[if gte vml 1]><v:group
 id="Group_x0020_17" o:spid="_x0000_s1041" style='position:absolute;left:0;
 text-align:left;margin-left:320.55pt;margin-top:-8.05pt;width:20.25pt;
 height:5.05pt;z-index:-251650048;mso-position-horizontal-relative:page'
 coordorigin="6411,-161" coordsize="405,101" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF
dyTewfKKEqcMCKEmHfgZgaE8wMW+SSwc27JvS/v23KTJgkoXFsu+P+c7Ol5vDoMTe0zZBl/LVVlJ
gV4HY31Xy4/tS3EvRSbwBlzwWMsjZrlprq/W22PELHjb51r2RPFBqax7HCCXIaLnThvSAMTP1KkI
+gs6VLdVdad08ISeCho1ZLN+whZ2jsTzgcsnJwldluLxNDiyagkxOquB2Knae/OLUsyEkjenmdzb
mG/YhlRnCWPnb8C898bRJGtQvEOiVxjYhtLOxs8AySiT4JuDystlVV4WPeM6tK3VaILeDZxIOSsu
ti/jidNGNZ3/J08yC1dNv9v8AAAA//8DAFBLAwQUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAF9y
ZWxzLy5yZWxzhI/NCsIwEITvgu8Q9m7TehCRpr2I4FX0AdZk2wbbJGTj39ubi6AgeJtl2G9m6vYx
jeJGka13CqqiBEFOe2Ndr+B03C3WIDihMzh6RwqexNA281l9oBFTfuLBBhaZ4ljBkFLYSMl6oAm5
8IFcdjofJ0z5jL0MqC/Yk1yW5UrGTwY0X0yxNwri3lQgjs+Qk/+zfddZTVuvrxO59CNCmoj3vCwj
MfaUFOjRhrPHaN4Wv0VV5OYgm1p+LW1eAAAA//8DAFBLAwQUAAYACAAAACEA33w4JIwEAABoDQAA
HwAAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWzsV9tu4zYQfS/QfyD42ELRJbRsGass
snYcFEjbYJ39AFqiLaESqZL0JS367x2SkiU78SbY7WMdICLNw+Gcw7nIHz4e6grtmFSl4CkOrwKM
GM9EXvJNir88LbwJRkpTntNKcJbiZ6bwx5sff/hApxtJm6LMEFjgakpTXGjdTH1fZQWrqboSDeOw
thayphqmcuPnku7Bcl35URDEfk1Ljm96U3OqKdrK8htMVSL7g+UzyndUgckqmw6/aX2ssu+3TKd8
dy+bZfMojefZb7tHico8xaAcpzVIhP12oYXB1D/btekNHNayNnixXqNDikkwDpLJCKNnGI9CEoUj
Z48dNMoAEI3G4RjWMwDEJLxul7Pi9zcMZMXd10yAi84VGAzcs0Pj3wXW4bijfS/FtkEwP6NvNlsr
D3BFyokBqt13ElzQBq32v4oc5KRbLWyQ/NdKgXqh1dkL47D1+qgRCVqNw8CuXZBHNU6bl+EQQuK4
eLgFAsuCNgxFk6M43QbVnMrivrea9BCIsLfUiCFSWjLAyl5BFzHXE+LCJTLfH4lA7G6VvmfChh/d
PShtt21yGNlLy1sCTxDa67qCDP/ZQwGK4zhC9rwW38HAAQf7yUdPAdojc/IZJuowztQkGL1q6rqD
GVPR66aA1dArEOBVU3CPvVfkdVNxh3FejS4QhFjvTcW9KdD0qBotOiGzA2+VhBGipqAGNpAboUyq
P7kLC9pbAZBR/QIWBIGEfx/WVY/3YYHSuV1g07suWaZRZaubtv9liiVGqxSv3NU2VBvGxnUzRPsU
m2s381rs2JOwK9oQjsgp43694kOcDdiBV91qj2+sPQjLAapf7fAOFZ6d6laBpHHX5sORgmE+yAku
FmVV2QCuuCEWRuPrxFJToipzs2rYKblZzSqJdhSEuiXmr73TE1gjlZ5TVTicXXISQuHkuT2mYDS/
a8ealpUbg1uVjQ3I6FZqk9u2Uf6dBMnd5G5CPBLFdx4J5nPvdjEjXryANjG/ns9m8/Af43NIpkWZ
54wbt7umHZIXHbEuMymUWOurTNQ+tKUyY13jhrYdBn3bPqF3osLCfl6q4J+6YeUHLt3TsgO6qu2u
+rC0BVYfPon82Wi9gieUQylcNMKbCwwKIf/CaA/vIylWf26pZBhVv3CV4iQkBMJE2wkZjSOYyOHK
arhCeQamUqwxpKsZzjTMYMu2keWmgJNCe/tcmJq+Lk3BBG+dT8a7Sumlfq6YvUzrOeP5I5X0M/hc
2RLAuPdl2QoDCNjek9sqtmw+Q8Y5u469lcOG2eVek3S9xmyGYyroNYkLLmi1fSOxvQZxMSsAxG6l
FHsTciBU1+SOcDiWD3a+pwVB2WxbUNdPuxZkmqh9YznvppCFkBWmCSEzgNoCBKzGXUMCPzqIFeEb
Es8lzzGbweJX0imMSPApSrxFPBl7ZEFGXjIOJl4QJp+SOCAJmS9O0+mh5Oz708mUl2QUjd6oLoH9
vMwrKLalZhBjZZ3iyRFEp5cqyrEaGPe79Oue/6fhxTSE4Glfif2z3xhWvPY3kfkhM5zf/AsAAP//
AwBQSwMEFAAGAAgAAAAhAJEtaklYBgAADxoAABoAAABjbGlwYm9hcmQvdGhlbWUvdGhlbWUxLnht
bOxZS28bNxC+F+h/WOy9sd6KjciBrUfcxE6CSEmRI6WldhlzlwuSsqNbkZx6KVAgLXpogN56KIoG
aIAGvfTHGHDQpj+iQ+5DpETFD7hAUMQCjN3Zb4bDmdlvSO6Nm09j6h1hLghLOn71WsX3cDJhAUnC
jv9wNPjsuu8JiZIAUZbgjj/Hwr+5/eknN9DWhJJ0zBAPRhGOsQeGErGFOn4kZbq1sSEmIEbiGktx
As+mjMdIwi0PNwKOjmGAmG7UKpXWRoxI4m+DRakM9Sn8S6RQggnlQ2UGewmKYfR70ymZYI0NDqsK
IeaiS7l3hGjHB5sBOx7hp9L3KBISHnT8iv7zN7ZvbKCtXInKNbqG3kD/5Xq5QnBY02PycFwO2mg0
G62d0r4GULmK67f7rX6rtKcBaDKBmWa+mDabu5u7vWaONUDZpcN2r92rVy28Yb++4vNOU/0svAZl
9hsr+MGgC1G08BqU4Zsr+EajXes2LLwGZfjWCr5d2ek12hZegyJKksMVdKXZqneL2ZaQKaN7Tvhm
szFo13LjCxRUQ1ldaogpS+S6WovRE8YHAFBAiiRJPDlP8RRNoCa7iJIxJ94+CSMovBQlTIC4UqsM
KnX4r34NfaUjgrYwMrSVX+CJWBEpfzwx4SSVHf82WPUNyOmbNyfPXp88+/3k+fOTZ7/mY2tTlt4e
SkJT791P3/zz8kvv799+fPfi22zoZbww8W9/+ertH3++zzzMeBGK0+9evX396vT7r//6+YXD+g5H
YxM+IjEW3l187D1gMUzQ4T8e84tpjCJETI2dJBQoQWoUh/2+jCz03TmiyIHbxXYcH3GgGhfw1uyJ
5fAw4jNJHBbvRLEFPGCM7jLujMIdNZYR5tEsCd2D85mJe4DQkWvsLkqsLPdnKXAscZnsRthy8z5F
iUQhTrD01DN2iLFjdo8JseJ6QCacCTaV3mPi7SLiDMmIjK1qWijtkRjyMnc5CPm2YnPwyNtl1DXr
Hj6ykfBuIOpwfoSpFcZbaCZR7DI5QjE1A76PZORycjjnExPXFxIyHWLKvH6AhXDp3OMwXyPpd4Bm
3Gk/oPPYRnJJDl029xFjJrLHDrsRilMXdkiSyMR+Lg6hRJF3n0kX/IDZb4i6hzygZG26HxFspfts
NngIDGu6tCgQ9WTGHbm8hZlVv8M5nSKsqQYagMXrMUnOJPklem/+d/QOJHr6w0vHjK6G0t2GrXxc
kMx3OHG+TXtLFL4Ot0zcXcYD8uHzdg/NkvsYXpXV5vWRtj/Stv+/p+117/PVk/WCn4G61bI1W67r
xXu8du0+JZQO5ZzifaGX7wK6UjAAodLTe1Rc7uXSCC7VmwwDWLiQI63jcSa/IDIaRiiFNX7VV0ZC
kZsOhZcyAUt/LXbaVng6iw9YkG1Zq1W1Pc3IQyC5kFeapRy2GzJDt9qLbVhpXnsb6u1y4YDSvYgT
xmC2E3WHE+1CqIKkN+cQNIcTemZX4sWmw4vrynyRqhUvwLUyK7Bs8mCx1fGbDVABJdhVIYoDlacs
1UV2dTKvMtPrgmlVAKwhigpYZHpT+bp2emp2WamdI9OWE0a52U7oyOgeJiIU4Lw6lfQ8blw015uL
lFruqVDo8aC0Fm60r7/Pi8vmGvSWuYEmJlPQxDvu+K16E0pmgtKOP4WtP1zGKdSOUMtdREM4NJtI
nr3wl2GWlAvZQyLKAq5JJ2ODmEjMPUrijq+mX6aBJppDtG/VGhDCB+vcJtDKh+YcJN1OMp5O8USa
aTckKtLZLTB8xhXOp1r98mClyWaQ7mEUHHtjOuMPEJRYs11VAQyIgBOgahbNgMCRZklki/pbakw5
7ZpnirqGMjmiaYTyjmKSeQbXVF66o+/KGBh3+ZwhoEZI8kY4DlWDNYNqddOya2Q+rO26ZyupyBmk
ueiZFquorulmMWuEog0sxfJyTd7wqggxcJrZ4TPqXqbczYLrltYJZZeAgJfxc3TdczQEw7XFYJZr
yuNVGlacnUvt3lFM8AzXztMkDNZvFWaX4lb2COdwILxU5we95aoF0bRYV+pIuz5PHKDUG4fVjg+f
COBs4ilcwUcGH2Q1JaspGVzBlwNoF9lxf8fPLwoJPM8kJaZeSOoFplFIGoWkWUiahaRVSFq+p8/F
4VuMOhL3veLYG3pYfkyery3sbzjb/wIAAP//AwBQSwMEFAAGAAgAAAAhAJxmRkG7AAAAJAEAACoA
AABjbGlwYm9hcmQvZHJhd2luZ3MvX3JlbHMvZHJhd2luZzEueG1sLnJlbHOEj80KwjAQhO+C7xD2
btJ6EJEmvYjQq9QHCMk2LTY/JFHs2xvoRUHwsjCz7DezTfuyM3liTJN3HGpaAUGnvJ6c4XDrL7sj
kJSl03L2DjksmKAV201zxVnmcpTGKSRSKC5xGHMOJ8aSGtHKRH1AVzaDj1bmIqNhQaq7NMj2VXVg
8ZMB4otJOs0hdroG0i+hJP9n+2GYFJ69elh0+UcEy6UXFqCMBjMHSldnnTUtXYGJhn39Jt4AAAD/
/wMAUEsBAi0AFAAGAAgAAAAhALvlSJQFAQAAHgIAABMAAAAAAAAAAAAAAAAAAAAAAFtDb250ZW50
X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAAAAAAAAAAAAAAA2AQAA
X3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEA33w4JIwEAABoDQAAHwAAAAAAAAAAAAAAAAAgAgAA
Y2xpcGJvYXJkL2RyYXdpbmdzL2RyYXdpbmcxLnhtbFBLAQItABQABgAIAAAAIQCRLWpJWAYAAA8a
AAAaAAAAAAAAAAAAAAAAAOkGAABjbGlwYm9hcmQvdGhlbWUvdGhlbWUxLnhtbFBLAQItABQABgAI
AAAAIQCcZkZBuwAAACQBAAAqAAAAAAAAAAAAAAAAAHkNAABjbGlwYm9hcmQvZHJhd2luZ3MvX3Jl
bHMvZHJhd2luZzEueG1sLnJlbHNQSwUGAAAAAAUABQBnAQAAfA4AAAAA
">
 <v:shape id="AutoShape_x0020_28" o:spid="_x0000_s1042" style='position:absolute;
  left:6421;top:-111;width:384;height:2;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="384,2" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m241,l384,m,l141,e" filled="f" strokecolor="#a4a4a4" strokeweight=".35386mm">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="241,0;384,0;0,0;141,0"
   o:connectangles="0,0,0,0"/>
 </v:shape><v:rect id="Rectangle_x0020_29" o:spid="_x0000_s1043" style='position:absolute;
  left:6562;top:-161;width:101;height:101;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" fillcolor="#a4a4a4" stroked="f"/>
 <w:wrap anchorx="page"/>
</v:group><![endif]--><img width="28" height="6" src="file:///C:/Users/alrasha1/AppData/Local/Temp/9/msohtmlclip1/01/clip_image004.png" />HARRIER</p><p>&nbsp;</p><p>Beovu 6 mg (n=360)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; aflibercept 2 mg (n=360)</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:group id="Group_x0020_9"
 o:spid="_x0000_s1033" style='position:absolute;left:0;text-align:left;
 margin-left:128.75pt;margin-top:8.9pt;width:362.05pt;height:167.6pt;z-index:251661312;
 mso-position-horizontal-relative:page' coordorigin="2575,178" coordsize="7241,3352"
 o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:line id="Line_x0020_14" o:spid="_x0000_s1034" style='position:absolute;
  visibility:visible;mso-wrap-style:square' from="2644,183" to="2644,3410"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight=".17636mm"/>
 <v:line id="Line_x0020_15" o:spid="_x0000_s1035" style='position:absolute;
  visibility:visible;mso-wrap-style:square' from="2695,3462" to="9747,3462"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight=".26456mm"/>
 <v:shape id="Freeform_x0020_16" o:spid="_x0000_s1036" style='position:absolute;
  left:2644;top:1200;width:7104;height:2263;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' coordsize="7104,2263" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,2262l296,1049,591,622,886,459r298,33l1479,459r295,-99l2072,197r295,-67l2662,163r298,l3255,130,3550,r298,65l4143,130r295,l4736,130r295,l5326,295r298,-98l5919,163r295,197l6512,197r295,65l7103,262e"
  filled="f" strokeweight=".35275mm">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,3462;296,2249;591,1822;886,1659;1184,1692;1479,1659;1774,1560;2072,1397;2367,1330;2662,1363;2960,1363;3255,1330;3550,1200;3848,1265;4143,1330;4438,1330;4736,1330;5031,1330;5326,1495;5624,1397;5919,1363;6214,1560;6512,1397;6807,1462;7103,1462"
   o:connectangles="0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0"/>
 </v:shape><v:shape id="AutoShape_x0020_17" o:spid="_x0000_s1037" style='position:absolute;
  left:2575;top:1130;width:7241;height:2400;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' coordsize="7241,2400" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m139,2330l69,2260,,2330r69,70l139,2330m434,1118r-69,-70l295,1118r70,70l434,1118m729,691l660,621r-70,70l660,760r69,-69m1025,528l955,458r-70,70l955,597r70,-69m1322,561r-69,-69l1183,561r70,70l1322,561t295,-33l1548,458r-70,70l1548,597r69,-69m1913,429r-70,-69l1773,429r70,70l1913,429m2210,266r-69,-70l2071,266r70,70l2210,266t295,-67l2436,129r-70,70l2436,268r69,-69m2801,232r-70,-69l2661,232r70,70l2801,232t297,l3029,163r-70,69l3029,302r69,-70m3393,199r-69,-70l3254,199r70,69l3393,199m3689,69l3619,r-70,69l3619,139r70,-70m3986,134l3917,64r-70,70l3917,204r69,-70m4281,199r-69,-70l4142,199r70,69l4281,199t296,l4507,129r-70,70l4507,268r70,-69m4874,199r-69,-70l4735,199r70,69l4874,199t295,l5100,129r-70,70l5100,268r69,-69m5465,364r-70,-69l5325,364r70,70l5465,364t297,-98l5693,196r-70,70l5693,336r69,-70m6057,232r-69,-69l5918,232r70,70l6057,232t296,197l6283,360r-70,69l6283,499r70,-70m6650,266r-69,-70l6511,266r70,70l6650,266t295,65l6876,261r-70,70l6876,400r69,-69m7241,331r-70,-70l7101,331r70,69l7241,331e"
  fillcolor="black" stroked="f">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="69,3390;69,3530;434,2248;295,2248;434,2248;660,1751;660,1890;1025,1658;885,1658;1025,1658;1253,1622;1253,1761;1617,1658;1478,1658;1617,1658;1843,1490;1843,1629;2210,1396;2071,1396;2210,1396;2436,1259;2436,1398;2801,1362;2661,1362;2801,1362;3029,1293;3029,1432;3393,1329;3254,1329;3393,1329;3619,1130;3619,1269;3986,1264;3847,1264;3986,1264;4212,1259;4212,1398;4577,1329;4437,1329;4577,1329;4805,1259;4805,1398;5169,1329;5030,1329;5169,1329;5395,1425;5395,1564;5762,1396;5623,1396;5762,1396;5988,1293;5988,1432;6353,1559;6213,1559;6353,1559;6581,1326;6581,1466;6945,1461;6806,1461;6945,1461;7171,1391;7171,1530"
   o:connectangles="0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0"/>
 </v:shape><v:shape id="Freeform_x0020_18" o:spid="_x0000_s1038" style='position:absolute;
  left:2644;top:839;width:7104;height:2623;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="7104,2623" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,2623l296,1081,591,656,886,524r298,34l1479,361r295,65l2072,196r295,33l2662,131r298,l3255,r295,164l3848,196r295,67l4438,196r298,67l5031,263r295,98l5624,392r295,68l6214,426r298,-65l6807,491r296,-31e"
  filled="f" strokecolor="#a4a4a4" strokeweight=".35275mm">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,3462;296,1920;591,1495;886,1363;1184,1397;1479,1200;1774,1265;2072,1035;2367,1068;2662,970;2960,970;3255,839;3550,1003;3848,1035;4143,1102;4438,1035;4736,1102;5031,1102;5326,1200;5624,1231;5919,1299;6214,1265;6512,1200;6807,1330;7103,1299"
   o:connectangles="0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0"/>
 </v:shape><v:shape id="AutoShape_x0020_19" o:spid="_x0000_s1039" style='position:absolute;
  left:2594;top:786;width:7203;height:2724;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="7203,2724" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m101,2624l,2624r,100l101,2724r,-100m396,1083r-101,l295,1184r101,l396,1083m691,658r-101,l590,759r101,l691,658m986,526r-100,l886,627r100,l986,526t298,34l1183,560r,100l1284,660r,-100m1579,363r-101,l1478,464r101,l1579,363t295,65l1774,428r,100l1874,528r,-100m2172,197r-101,l2071,298r101,l2172,197t295,34l2366,231r,101l2467,332r,-101m2762,132r-100,l2662,233r100,l2762,132t298,l2959,132r,101l3060,233r,-101m3355,l3254,r,101l3355,101,3355,t295,166l3550,166r,101l3650,267r,-101m3948,197r-101,l3847,298r101,l3948,197t295,67l4142,264r,101l4243,365r,-101m4538,197r-100,l4438,298r100,l4538,197t298,67l4735,264r,101l4836,365r,-101m5131,264r-101,l5030,365r101,l5131,264t295,99l5326,363r,101l5426,464r,-101m5724,394r-101,l5623,495r101,l5724,394t295,67l5918,461r,101l6019,562r,-101m6314,428r-100,l6214,528r100,l6314,428t298,-65l6511,363r,101l6612,464r,-101m6907,492r-101,l6806,593r101,l6907,492t295,-31l7102,461r,101l7202,562r,-101e"
  fillcolor="#a4a4a4" stroked="f">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,3410;101,3510;396,1869;295,1970;396,1869;590,1444;691,1545;986,1312;886,1413;986,1312;1183,1346;1284,1446;1579,1149;1478,1250;1579,1149;1774,1214;1874,1314;2172,983;2071,1084;2172,983;2366,1017;2467,1118;2762,918;2662,1019;2762,918;2959,918;3060,1019;3355,786;3254,887;3355,786;3550,952;3650,1053;3948,983;3847,1084;3948,983;4142,1050;4243,1151;4538,983;4438,1084;4538,983;4735,1050;4836,1151;5131,1050;5030,1151;5131,1050;5326,1149;5426,1250;5724,1180;5623,1281;5724,1180;5918,1247;6019,1348;6314,1214;6214,1314;6314,1214;6511,1149;6612,1250;6907,1278;6806,1379;6907,1278;7102,1247;7202,1348"
   o:connectangles="0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0"/>
 </v:shape><v:shape id="AutoShape_x0020_20" o:spid="_x0000_s1040" style='position:absolute;
  left:6185;top:1241;width:3558;height:2242;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' coordsize="3558,2242" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m3558,289r,1952m,l,2229e" filled="f" strokecolor="#a4a4a4"
  strokeweight=".5pt">
  <v:stroke dashstyle="3 1"/>
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="3558,1530;3558,3482;0,1241;0,3470"
   o:connectangles="0,0,0,0"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="484" height="225" src="file:///C:/Users/alrasha1/AppData/Local/Temp/9/msohtmlclip1/01/clip_image005.png" />10</p><p><!--[if gte vml 1]><v:shape id="Text_x0020_Box_x0020_8"
 o:spid="_x0000_s1032" type="#_x0000_t202" style='position:absolute;left:0;
 text-align:left;margin-left:87pt;margin-top:18.4pt;width:11pt;height:124pt;
 z-index:251663360;visibility:visible;mso-wrap-style:square;
 mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
 mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:page;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" stroked="f">
 <v:textbox style='layout-flow:vertical;mso-layout-flow-alt:bottom-to-top'
  inset="0,0,0,0">
  <![if RotText]><![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal style='margin-top:0in;margin-right:-21.1pt;margin-bottom:
    0in;margin-left:1.0pt;margin-bottom:.0001pt;line-height:10.15pt;mso-line-height-rule:
    exactly'><span style='font-size:9.0pt;mso-bidi-font-size:11.0pt;font-family:
    "Calibri",sans-serif;mso-hansi-font-family:"Times New Roman";mso-bidi-font-family:
    "Times New Roman"'>VA<span style='letter-spacing:-.1pt'> </span>c<span
    style='letter-spacing:-.05pt'>h</span>a<span style='letter-spacing:-.05pt'>ng</span>e<span
    style='letter-spacing:.05pt'> </span><span style='letter-spacing:-.05pt'>fr</span>om<span
    style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.05pt'>b</span>a<span
    style='letter-spacing:-.05pt'>selin</span>e<span style='letter-spacing:
    .3pt'> </span>(<span style='letter-spacing:-.05pt'>le</span>t<span
    style='letter-spacing:-.05pt'>te</span>r<span style='letter-spacing:-.1pt'>s</span>)<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]><![endif]></v:textbox>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="19" height="170" alt="Text Box: VA change from baseline (letters)" src="file:///C:/Users/alrasha1/AppData/Local/Temp/9/msohtmlclip1/01/clip_image006.png" />9</p><p>8</p><p>7</p><p>6</p><p>5</p><p>4</p><p>3</p><p>2</p><p>1</p><p>0</p><p>0&nbsp;&nbsp;&nbsp; 4&nbsp;&nbsp;&nbsp;&nbsp; 8&nbsp; &nbsp;12 &nbsp;16 &nbsp;20 &nbsp;24 &nbsp;28 &nbsp;32 &nbsp;36 &nbsp;40 &nbsp;44 &nbsp;48 &nbsp;52 &nbsp;56 &nbsp;60 &nbsp;64 &nbsp;68 &nbsp;72 &nbsp;76 &nbsp;80 &nbsp;84 &nbsp;88 &nbsp;92 &nbsp;96</p><p>&nbsp;</p><p>Time (weeks)</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:group
 id="Group_x0020_5" o:spid="_x0000_s1029" style='position:absolute;left:0;
 text-align:left;margin-left:199.55pt;margin-top:6.55pt;width:20.2pt;height:5.05pt;
 z-index:251662336;mso-position-horizontal-relative:page' coordorigin="3991,131"
 coordsize="404,101" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:line id="Line_x0020_22" o:spid="_x0000_s1030" style='position:absolute;
  visibility:visible;mso-wrap-style:square' from="4001,182" to="4385,182"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" strokeweight=".35275mm"/>
 <v:shape id="Freeform_x0020_23" o:spid="_x0000_s1031" style='position:absolute;
  left:4142;top:131;width:101;height:101;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="101,101" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m51,l,50r51,51l101,50,51,xe" fillcolor="black" stroked="f">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="51,131;0,181;51,232;101,181;51,131"
   o:connectangles="0,0,0,0,0"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="27" height="8" src="file:///C:/Users/alrasha1/AppData/Local/Temp/9/msohtmlclip1/01/clip_image007.png" /><!--[if gte vml 1]><v:group
 id="Group_x0020_2" o:spid="_x0000_s1026" style='position:absolute;left:0;
 text-align:left;margin-left:311pt;margin-top:6.55pt;width:20.2pt;height:5.05pt;
 z-index:-251649024;mso-position-horizontal-relative:page' coordorigin="6220,131"
 coordsize="404,101" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shape id="AutoShape_x0020_31" o:spid="_x0000_s1027" style='position:absolute;
  left:6230;top:182;width:384;height:2;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="384,2" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m243,l384,m,l142,e" filled="f" strokecolor="#a4a4a4" strokeweight=".35275mm">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="243,0;384,0;0,0;142,0"
   o:connectangles="0,0,0,0"/>
 </v:shape><v:rect id="Rectangle_x0020_32" o:spid="_x0000_s1028" style='position:absolute;
  left:6372;top:131;width:101;height:101;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" fillcolor="#a4a4a4" stroked="f"/>
 <w:wrap anchorx="page"/>
</v:group><![endif]--><img width="28" height="6" src="file:///C:/Users/alrasha1/AppData/Local/Temp/9/msohtmlclip1/01/clip_image008.png" />Beovu 6 mg (n=370)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; aflibercept 2 mg (n=369)</p><p>&nbsp;</p><p>These visual acuity gains were achieved with 56% and 51% of patients treated with Beovu 6 mg on a 12-weekly dosing interval at week 48, and with 45% and 39% of patients at week 96 in HAWK and HARRIER, respectively. Among patients identified as eligible for the 12-weekly regimen during the first 12-week interval, 85% and 82% remained on the 12-weekly dosing interval up to week 48. Of patients on the 12-weekly interval at week 48, 82% and 75% remained on the 12-weekly dosing interval up to week 96.</p><p>&nbsp;</p><p>Treatment effects in evaluable subgroups (e.g. age, gender, race, baseline visual acuity, baseline retinal thickness, lesion type, lesion size, fluid status) in each study were generally consistent with the results in the overall populations.</p><p>&nbsp;</p><p>Disease activity was assessed by changes in visual acuity and/or anatomical parameters, including CST and/or presence of IRF/SRF or sub-RPE. Disease activity was assessed throughout the studies. Anatomical parameters of disease activity were decreased at week 48 and at week 96 for Beovu compared to aflibercept (see &ldquo;Pharmacodynamic effects&rdquo;).</p><p>&nbsp;</p><p>The percentage difference in patients with disease activity at week 16 was statistically significant on Beovu versus aflibercept (24% vs 35% in HAWK, p=0.0013; 23% vs 32% in HARRIER, p=0.0021).</p><p>&nbsp;</p><p>In both studies, Beovu demonstrated clinically meaningful increases from baseline in the pre-specified secondary efficacy endpoint of patient-reported outcomes, reported through the National Eye Institute Visual Function Questionnaire (NEI VFQ-25). The magnitude of these changes was similar to that seen in published studies, which corresponded to a 15-letter gain in BCVA. Patient-reported outcome benefits were maintained in the second year.</p><p>&nbsp;</p><p>No clinically meaningful differences were found between Beovu and aflibercept in changes from baseline to week 48 in NEI VFQ-25 total score and subscales (general vision, ocular pain, near activities, distance activities, social functioning, mental health, role difficulties, dependency, driving, colour vision and peripheral vision).</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The European Medicines Agency has waived the obligation to submit the results of studies with Beovu in all subsets of the paediatric population in neovascular AMD (see section 4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Beovu is administered directly into the vitreous to exert local effects in the eye. <u>Absorption and distribution</u></p><p>After intravitreal administration of 6 mg brolucizumab per eye to patients with nAMD, the geometirc mean Cmax of free brolucizumab in the plasma was 49.0 ng/ml (range: 8.97 to 548 ng/ml) and was attained in 1 day.</p><p>&nbsp;</p><p><u>Biotransformation and elimination</u></p><p>&nbsp;</p><p>Brolucizumab is a monoclonal antibody fragment and no metabolism studies have been conducted. As a single-chain antibody fragment, free brolucizumab is expected to undergo elimination through both target-mediated disposition via binding to free endogenous VEGF, passive renal elimination and metabolism via proteolysis.</p><p>&nbsp;</p><p>After intravitreal injections, brolucizumab was eliminated with an apparent systemic half-life of</p><p>4.4 days. Concentrations were generally near or below the quantitation limit (&lt;0.5 ng/ml) approximately 4 weeks after dosing in most patients. Brolucizumab did not accumulate in the serum when administered intravitreally every 4 weeks.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em><u>Elderly</u></em></p><p>There were no relevant differences in systemic pharmacokinetics following intravitreal injection in a study with 22 patients aged 65 to 74 years, 18 patients aged 75 to 84 years and 3 patients aged</p><p>&ge;85 years.</p><p>&nbsp;</p><p><em><u>Renal impairment</u></em></p><p>The systemic pharmacokinetics of brolucizumab was evaluated in nAMD patients with normal renal function (&ge;90 ml/min [n=21]), with mild (60 to &lt;90 ml/min [n=22]) or moderate (30 to &lt;60 ml/min [n=7]) renal impairment. While the mean systemic clearance values for patients with mild or moderate renal impairment were generally lower than patients with normal renal function, no significant impact of mild and moderate renal impairment on the overall systemic exposure to brolucizumab was observed. No patients with severe (&lt;30 ml/min) renal impairment were studied.</p><p>&nbsp;</p><p><em><u>Hepatic impairment</u></em></p><p>Brolucizumab has not been studied in patients with hepatic impairment. Mild to severe hepatic impairment should have no impact on the overall systemic exposure to brolucizumab, because metabolism occurs via proteolysis and does not depend on hepatic function.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies have been conducted on the carcinogenic or mutagenic potential of brolucizumab. No animal reproduction studies have been conducted.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium citrate Sucrose Polysorbate 80 Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Shelf life for both Pre-filled syringe and Vial is 2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pre-filled syringe</u></p><p>&nbsp;</p><p>Store in a refrigerator (2&deg;C - 8&deg;C). Do not freeze.</p><p>Keep the pre-filled syringe in its sealed blister and in the outer carton in order to protect from light. Prior to use, the unopened blister may be kept at room temperature (below 30&deg;C) for up to 24 hours.</p><p>&nbsp;</p><p><u>Vial</u></p><p>&nbsp;</p><p>Store in a refrigerator (2&deg;C - 8&deg;C). Do not freeze.</p><p>Keep the vial in the outer carton in order to protect from light.</p><p>Prior to use, the unopened vial may be kept at room temperature (below 30&deg;C) for up to 24 hours.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pre-filled syringe</u></p><p>&nbsp;</p><p>0.165 ml sterile solution in a pre-filled syringe (type I glass) with a bromobutyl rubber plunger stopper and a syringe cap consisting of a white, tamper-evident rigid seal with a grey bromobutyl rubber tip cap including a Luer lock adapter. The pre-filled syringe has a plunger rod and a purple finger grip, and is packed in a sealed blister.</p><p>&nbsp;</p><p>Pack size of 1 pre-filled syringe. <u>Vial</u></p><p>0.230 ml sterile solution in a glass vial with a coated rubber stopper sealed with an aluminium cap with a purple plastic flip-off disk.</p><p>&nbsp;</p><p>Pack size of 1 vial and 1 blunt filter needle (18G x 1&frac12;&Prime;, 1.2 mm x 40 mm, 5 &mu;m).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pre-filled syringe</u></p><p>&nbsp;</p><p>The pre-filled syringe contains more than the recommended dose of 6 mg. The extractable volume of the pre-filled syringe (0.165 ml) is not to be used in total. The excess volume should be expelled prior to injection. Injecting the entire volume of the pre-filled syringe could result in overdose. To expel the air bubble along with the excess medicinal product, slowly push the plunger until the edge below the dome of the rubber stopper is aligned with the black dosing line on the syringe (equivalent to 0.05 ml, i.e., 6 mg brolucizumab).</p><p>&nbsp;</p><p>The solution should be inspected visually upon removal from the refrigerator and prior to administration. If particulates or cloudiness are visible, the pre-filled syringe must not be used and appropriate replacement procedures followed.</p><p>&nbsp;</p><p>The pre-filled syringe is sterile and for single use only. Do not use if the packaging, or pre-filled syringe are damaged or expired. Detailed instructions for use are provided in the package leaflet.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local regulations.</p><p>&nbsp;</p><p><u>Vial</u></p><p>&nbsp;</p><p>The vial contains more than the recommended dose of 6 mg. The extractable volume of the vial (0.23 ml) is not to be used in total. The excess volume should be expelled prior to injection. Injecting the entire volume of the vial could result in overdose. The injection dose must be set to the 0.05 ml dose mark, i.e. 6 mg brolucizumab.</p><p>&nbsp;</p><p>The solution should be inspected visually upon removal from the refrigerator and prior to administration. If particulates or cloudiness are visible, the vial must not be used, and appropriate replacement procedures must be followed.</p><p>&nbsp;</p><p>The content of the vial and the filter needle are sterile and for single use only. Do not use if the packaging, vial and/or filter needle are damaged or expired. Detailed instructions for use are provided in the package leaflet.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Marketing Authorization Holder for this Product is Novartis Europharm Limited, Ireland
www.Novartis.com 

•	Manufacturers;
o	Pre-filled syringe: Manufactured by Alcon-Couvreur, Puurs, Belgium
o	Vial: Manufactured by Novartis Pharma AG, Stein, Switzerland

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Approved by EMA in 11/2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>